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ABSTRACT 
Spore germination is a significant step in the transformation of dormant spores into 
exponentially dividing vegetative cells, and in the case of Clostridium botulinum in the 
formation of the deadly botulinum neurotoxin. The ability of nutrient and non-nutrient 
germinants to induce germination of strains Af84 (C. botulinum Group I) and Eklund 17B (C. 
botulinum Group II) was established by measuring the change in optical density and by 
microscopic observation. Germination of strains Af84 and Eklund 17B was initiated by the 
nutrient germinants L-alanine and L-cysteine and the non-nutrient germinants 
dodecylamine (DDA) and lysozyme, but not by calcium dipicolinic acid (CaDPA). Heating 
spores of strain Af84 for 4 hours at 95°C delivered a 3-log reduction in viability. Heat 
damaged spores of strain Af84 could not be recovered using lysozyme, L-alanine or DDA. 
Thermal death of spores of strain Eklund 17B occurred within 2 minutes of heating at 85°C, 
and resulted in a 5-log reduction in viability. The presence of lysozyme (10μg/ml) increased 
the recovery of heat damaged spores of strain Eklund 17B, however, the presence of L-
alanine and DDA had no effect. The timing of DPA release in relation to cortex hydrolysis is 
still unknown in C. botulinum, however this study found that DPA is released within 18 
hours of germinant addition in strain Af84 and within 50 minutes for strain Eklund 17B. In 
addition, the average DPA concentration per spore of strains Af84 and Eklund 17B was 
shown to be 1.9pg and 2.1pg, respectively. Results obtained indicate that part of the 
germination apparatus in Group II strain Eklund 17B is damaged by heating, rather than the 
spore DNA. Understanding the mechanisms involved in spore germination can improve the 
control of botulinum neurotoxin forming clostridia, prevent foodborne botulism, and 
thereby contribute to the microbiological safety of foods. 
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1. Introduction  
Clostridium is a phylogenetically diverse genus of the phylum Firmicutes, encompassing 
approximately 110 heterogeneous bacteria of both medical and environmental importance 
(Kalia et al., 2011, Kunisawa, 2015). Members of the order Clostridiales are Gram-positive, 
spore forming, obligately anaerobic bacteria, which include major pathogenic organisms 
such as Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium 
tetani and Clostridium sordellii (Swick et al., 2016).  Comparison of the genomes of 
sequenced Clostridia shows wide genetic variability in the genus and even substantial 
variability amongst organisms of the same species (Sebaihia et al., 2007). C. botulinum is 
defined by the ability to form the botulinum neurotoxin and thus the capability to cause 
botulism in humans and/or animals, rather than by close phylogeny (Peck, 2009). C. 
botulinum can be divided into four distinct groups (I-IV) based on their genetic and 
physiological properties, and the botulinum neurotoxin can be subdivided into seven 
serotypes (A to G) (Peck, 2009). 
C. botulinum Group I strains are highly proteolytic and can degrade certain carbohydrates, 
such as glucose. These strains form botulinum neurotoxin of types A, B and/or F. C. 
botulinum Group I can be described as mesophilic with an optimum growth temperature of 
37°C and a minimum growth temperature of 10-12°C (Lund and Peck, 2000, Peck et al., 
2011). However, in a recent study it was established that C. botulinum Group I type B 
strains grew considerably faster at 42°C than at 37°C (Hinderink et al., 2009). Highly heat 
resistant spores are produced by C. botulinum Group I and the “botulinum cook” (121°C/ 3 
min) is given to inactivate spores and thereby prevent subsequent growth in low acid 
canned foods (Carter and Peck, 2015). Growth and toxin formation by C. botulinum Group I 
is prevented at a pH of ≤ 4.6 or 10% NaCl. The minimum water activity [aw] for growth of 
proteolytic C. botulinum is 0.96 for NaCl and 0.93 with glycerol (Lund and Peck, 2000). C. 
botulinum Group I strains are closely related to Clostridium sporogenes and therefore, it is 
often used as a surrogate organism for thermal processing experiments in food due to its 
similar spore heat resistance (Bradbury et al., 2012, McClung, 1937). 
C. botulinum Group II (non-proteolytic) are highly saccharolytic bacteria capable of 
metabolising a wide range of carbohydrates, including glucose, maltose, fructose, sucrose 
and mannose. C. botulinum Group II strains form a single neurotoxin of type B, E or F and 
have an optimum growth temperature of 25°C-30°C (Lund and Peck, 2000, Peck, 2009). C. 
botulinum Group II grows at a minimum temperature of 2.5-3.0°C and is a concern for 
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minimally heated chilled foods, such as chilled ready meals. The safety of these foods relies 
on a combination of mild heat treatment, chilled storage, a limited shelf-life and 
occasionally preservatives.  Growth of C. botulinum Group II is prevented by a pH < 5 or a 
NaCl concentration ≥ 5%. The minimum water activity for growth of C. botulinum Group II is 
slightly higher than the water activity for C. botulinum Group I (0.97 and 0.94 for NaCl and 
glycerol, respectively). Spores of C. botulinum Group II are less heat resistant than spores of 
C. botulinum Group I (Peck, 2014). 
C. botulinum Group III is mainly associated with avian and non-human mammalian botulism 
(Skarin et al., 2011). C. botulinum Group III is a mesophilic organism with the ability to 
metabolise sugars, and a minimum and optimum growth temperature of 15°C and 40°C, 
respectively. Inhibition of growth of C. botulinum Group III occurs at a pH of < 5.1 (Lund and 
Peck, 2000). Strains of C. botulinum Group III produce neurotoxin genes of type C or D, 
however, genetic analysis of isolates from avian species revealed that the neurotoxin gene 
commonly comprises of two thirds of a gene of one toxin type and one third of a gene of 
the other toxin type and therefore is often referred to as a type C/D or D/C mosaic 
neurotoxin (Moriishi et al., 1996, Takeda et al., 2005). Analysis of 16S rDNA sequences 
indicate that strains of C. botulinum Group III are more similar genetically to Clostridium 
novyi and Clostridium haemolyticum than C. botulinum Groups I and II (Sasaki et al., 2001).  
Clostridium argentinense, also called C. botulinum Group IV, is a mesophilic bacterium with 
an optimal growth temperature of 37°C. C. argentinense produces toxin type G, however 
the bacterium has not been associated with human, avian or animal botulism outside of a 
laboratory (Lund and Peck, 2000, Suen et al., 1988).  
 
1.1 Botulinum Neurotoxins 
Seven distinct botulinum neurotoxin serotypes (A-G) have been identified, differing in their 
amino acid sequence by 37-70% (Hill et al., 2015). An eighth potential neurotoxin type has 
been identified within the last four years and has been referred to as a variety of names in 
recent papers, such as serotype H, FA or HA (Dover et al., 2014, Maslanka et al., 2016, Peck 
et al., 2017). Heterogeneity in these serotypes has led to the identification of 
approximately 40 subtypes, which have variability of up to 36% in amino acid sequence 
within each toxin type (Hill and Smith, 2012, Peck et al., 2017). Serotypes A and F have the 
greatest difference within their subtypes at 16% and 36% respectively, whereas serotype B 
(7%) and serotype E (6%) show less variance at the amino acid level (Dorner et al., 2012, 
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Peck et al., 2017). Botulinum neurotoxin of all types consist of a 100-kDa heavy chain (H) 
connected via a disulphide bond to a 50-kDa light chain (L) (Hatheway, 1990). The heavy 
chain consists of two functional domains, the C-domain and N-terminal domain, which are 
involved in neurotoxin binding to the nerve cell and movement of the light chain into the 
nerve cell cytoplasm (Carter and Peck, 2015). Light chains are zinc-endopeptidases which 
are active in the nerve cell and function by selectively cleaving proteins involved in the 
neurotransmitter-vesicle docking and fusion complex, preventing neurotransmitter release 
which ultimately results in flaccid paralysis, typical of botulism (Poulain et al., 2008, 
Rossetto et al., 2014).  
 C. botulinum Group I strains can produce one, two or three neurotoxin of types, A, B and F, 
and can possess up to three neurotoxin genes located on a large plasmid or chromosome. 
Whereas, C. botulinum Group II strains contain one toxin gene and form a single toxin of 
type B, E or F (Hill et al., 2009). In C. botulinum Group II, the neurotoxin gene for serotype B 
is situated on a small plasmid, whereas the type F neurotoxin gene is located on the 
chromosome. The type E botulinum neurotoxin gene can be located on either the 
chromosome, most commonly, or on a plasmid; however only 6% of Group II strains 
analysed in a recent study by Carter et al. (2016) exhibited neurotoxin-encoding genes 
located on the plasmid. Some strains producing neurotoxin type F have fragments of both 
type B and E neurotoxin genes (Carter et al., 2013). In C. botulinum Group III, neurotoxin 
genes are located on bacteriophages, and in C. botulinum Group IV the neurotoxin gene is 
situated on a plasmid (Carter et al., 2016, Zhang et al., 2013). The botulinum toxins that 
most commonly cause human botulism are serotypes A, B, E and F. Where strains produce 
two type of toxins, the uppercase letter denotes the dominant toxin (e.g. Ab) (Carter and 
Peck, 2015). 
 The botulinum neurotoxin forms progenitor protein complexes via covalent bonds with 
non-toxigenic proteins. There are two types of botulinum neurotoxin gene cluster (orfX+ 
and ha+) (Chen et al., 2008, Connan et al., 2013). The botulinum neurotoxin gene clusters 
are in the region of 11-14kb, encoding between three and seven proteins to give the 
neurotoxin complex (Smith et al., 2007). Both clusters, orfX+ and ha+, contain a nontoxin-
nonhaemagglutinin encoding gene (ntnh) adjacent to the botulinum neurotoxin gene (bont) 
(Smith et al., 2007).  The orfX+ gene cluster (Figure 1(a)) contains a neurotoxin gene (bont), 
a nontoxin-nonhaemagglutinin (ntnh) gene, a regulatory gene (botR) and a gene (p47) of 
unknown function, and three other genes of unknown function (orfX1, X2, X3). Neurotoxins 
of serotypes A, E and F are formed by the orfX+ gene cluster. The second protein complex 
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found with neurotoxin of serotypes A, B, C, D and G is encoded by the haemagglutinin gene 
cluster (ha+) (Figure 1(b)), in which the orfX1-X3 genes are replaced with three 
haemagglutinin encoding genes (ha70, ha17, ha33) (Chen et al., 2008, Hill and Smith, 
2012). The botR gene is situated at the 5’ end of the botulinum locus in toxin serotypes C 
and D, whereas in C. botulinum types A, B and G, the botR gene is located between the 
ntnh-bont and ha genes (Raffestin et al., 2004). Botulinum neurotoxin type A is the only 
toxin that can be encoded by either gene cluster (orfX+ or ha+). New subtypes have arisen 
through recombination events (Hill et al., 2015).  
 
A recent study has identified 41 botulinum subtypes which all display inter- and less 
frequently intra-subtype differences (Peck and van Vliet, 2016). The term subtype can be 
used to describe variation amongst neurotoxin serotype based on amino acid sequence 
(Peck et al., 2017). Only strains of C. botulinum Group I produce toxin serotype A, and this 
serotype can be categorised into eight toxin subtypes (A1-A8). Although subtypes exist, 
type B and E toxins display less than 2.6% variability in their amino acid sequence. The most 
significant difference in neurotoxin variability occurs in serotype F, where subtypes F5 and 
F7 show the greatest dissimilarity (Peck and van Vliet, 2016). C. botulinum Group II type F 
carries the F6 neurotoxin gene exclusively, whereas Group I C. botulinum type F can carry 
neurotoxin genes of F1-F5 (Raphael et al., 2010).  A novel neurotoxin has recently been 
proposed in the literature containing regions of type A and F toxin types and therefore is 
Figure 1. Gene arrangement in the botulinum neurotoxin gene clusters orfX+ (a) for 
serotype A, E and F and ha+ (b) for serotype A, B, C, D and G. C. botulinum Group II strains 
of serotype E and F do not contain the botR encoding gene. The botulinum toxin is 
depicted as bont (Adapted from Hill et al. (2015)).  
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referred to as type FA (or H/HA) (Dover et al., 2014, Fan et al., 2016, Kalb et al., 2015). As 
mentioned previously, hybrid neurotoxins composed of both type C and D toxins (often 
referred to as mosaic neurotoxins) can occur and are formed more frequently than single 
neurotoxins of type C or D (Woudstra et al., 2012). Hybrid subtypes, composed of two 
other subtypes, have been identified in the literature, for example, botulinum neurotoxin 
subtype A2 is an amalgam of subtypes A1 and A3. Likewise, botulinum neurotoxin F6 is a 
hybrid of subtypes F1 and F2 (Hill and Smith, 2013). 
 
1.2 Botulism 
1.2.1 History of Botulism  
The first strain of C. botulinum was described in 1897 when Emile van Ermengem isolated 
an anaerobic, spore-forming, toxin producing Bacillus from the remnants of a salted ham 
which had been eaten by 34 musicians in a Belgium restaurant in 1895, resulting in severe 
neuroparalytic disease and 3 fatalities (Collins and East, 1998). However, symptoms of 
botulism had been reported almost 100 years previously in Germany and a large outbreak 
of botulism associated with the consumption of a locally produced blood sausage in 1802 
resulted in the acquisition of the term ‘botulism’ from the latin ‘botulus', meaning sausage 
(Peck, 2014). Historically, C. botulinum was named Bacillus botulinus by van Ermengem 
until the separation of the Bacillus genus from the Clostridium genus due to differences in 
their aerobic and anaerobic growth requirements (Winslow et al., 1917).  An investigation 
by Landmann in 1904 reported a large outbreak of botulism associated with canned white 
beans in Darmstadt, Germany.  An anaerobic bacterium, similar to the one isolated by van 
Ermengem, was found to be the causative agent, however, further analysis revealed that 
the neurotoxin produced was different to the one found previously (Peck, 2014). 
Heterologous toxins produced by different strains of C. botulinum were first recognised by 
Leuchs in 1910 on production of an antitoxin for the van Ermengem and Landmann strains. 
During this investigation, Leuchs discovered that the antitoxin produced for one toxin did 
not protect against the toxin formed by the other strain (Burke, 1919).  
Serological methods were introduced shortly after the isolation of the Landmann strain of 
C. botulinum to classify the bacteria by the toxin produced. Antiserum produced by one 
toxin was used to neutralise toxin or agglutinate bacteria of different isolates, initially 
resulting in the identification of two toxin serotypes, A and B (Burke, 1919). Agglutination 
methods separated the C. botulinum toxins into different agglutination groups (Schoenholz 
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and Meyer, 1925). C. botulinum continues to be classified on the ability to produce the 
botulinum neurotoxin, however, repeated sub-culturing of a single strain of C. botulinum in 
a laboratory can result in a loss of toxigenicity and therefore it is difficult to rely on the 
agglutination method to differentiate between strains of C. botulinum (Gunnison and 
Meyer, 1929, Smith et al., 2015).  
In 1947, a simple method using egg yolk agar was introduced to detect botulinum 
neurotoxin producing strains in mixed cultures (McClung and Toabe, 1947). Strains of C. 
botulinum are distinguished from other organisms in a mixed culture by their interaction 
with lipase and lecithinase on egg yolk agar. A positive lipase reaction results in colony 
growth with an oily sheen, whereas a positive lecithinase reaction causes a white opaque 
ring to appear below the surface of the colony in the agar. C. botulinum can be identified 
on egg yolk agar due to its positive and negative reaction with lipase and lecithinase, 
respectively. However, closely related organisms, such as C. sporogenes, also react with 
lipase and lecithinase and therefore it may be difficult to differentiate between clostridia 
(McClung and Toabe, 1947). Some strains of C. botulinum produced variable results with 
lipase and lecithinase and therefore it has been concluded that this method for identifying 
C. botulinum cannot be used as the sole technique (Smith et al., 2015).   
 
1.2.2 Foodborne Botulism 
Foodborne botulism is caused by ingesting food contaminated with toxin formed by a 
strain of C. botulinum Group I or Group II. The incubation period for the onset of symptoms 
of foodborne botulism usually occurs between 2 hours and 8 days after ingestion of 
contaminated food, depending on the toxin serotype and dose of toxin consumed. The 
main clinical manifestation of foodborne botulism is a descending, symmetrical flaccid 
paralysis (Wenham and Cohen, 2008). Patients often present with a combination of 
symptoms, therefore respiratory failure may occur before botulism is diagnosed (Wictome 
and Shone, 1998). Suspected botulism cases can often be confused with other diseases 
with similar symptoms due to the rarity of botulism in the UK (Wenham and Cohen, 2008). 
The botulinum neurotoxin is the most potent toxin known.  Extrapolation from foodborne 
botulinum outbreaks and primate studies have enabled the lethal dose of botulinum 
neurotoxin in humans to be estimated as 30-100ng. Outbreaks of foodborne botulism are 
often associated with improper canning and bottling procedures which are used to 
enhance a product’s shelf life (Peck, 2009). In the USA between 1918 and 1924 there were 
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230 fatal cases of foodborne botulism reported (Meyer and Eddie, 1965). In August 1922, 
the first outbreak of foodborne botulism, resulting in eight fatalities, in the UK was 
associated with the consumption of under-processed wild duck paste (Leighton, 1923). The 
‘botulinum cook’ was developed after research on C. botulinum Group I spore heat 
resistance was conducted and concluded that a standard minimum heat treatment should 
be given to all low-acid canned foods to prevent C. botulinum spore germination,  growth 
and toxin formation (Esty and Meyer, 1922). The number of foodborne botulism cases in 
Europe exceeded 2500 in 1999/2000 and the majority of cases were reported from Russia 
(887 cases), Belarus (344 cases) and Azerbaijan (181 cases) (Peck, 2006). 
Inadequate processing of canned or bottled foods is not the only source of foodborne 
botulism. In recent years, outbreaks have been associated with poor refrigeration of foods 
allowing neurotoxin formation (Peck, 2009). Foodborne botulism caused by C. botulinum 
Group I usually involves neurotoxin types A and B, with outbreaks caused by C. botulinum 
Group II most frequently associated with type B or E toxins (Peck, 2009). One of the largest 
economically devastating outbreaks of foodborne botulism occurred in Augusta, Georgia 
(USA) in June 2007 when four cases of botulism were reported and linked to the 
consumption of contaminated hot dog chilli sauce, which led to more than one hundred 
million cans being recalled and closure of the manufacturing plant (CDC, 2007). The largest 
UK outbreak of foodborne botulism occurred in June 1989 and was associated with 
contaminated hazelnut yoghurt resulting in 27 symptomatic patients and 1 fatality. 
Hazelnut conserve that had been improperly heat treated was contaminated with spores of 
C. botulinum Group I type B, which germinated leading to growth and neurotoxin formation 
in the conserve. The conserve, containing the toxin, was then combined with natural 
yoghurt and sold to the public (O'Mahony et al., 1990). A severe case of botulism was also 
associated with improper storage of commercial chilled carrot juice in Canada and the USA 
in 2006. Large amounts of toxin were present in the carrot juice, and it was estimated that 
consuming approximately 5µl of the contaminated carrot juice would constitute a lethal 
dose and consequently all six patients, one of which died, required medical ventilation 
(CDC, 2006, Sheth et al., 2008). 
 The largest outbreak of botulism since 1978 in the USA was reported in June 2016 and was 
caused by the consumption of an illicit alcohol drink, termed “hooch”, in a medium security 
federal correctional facility in Mississippi. In total, 31 inmates showed symptoms of 
botulism after consuming “hooch” and 24 patients required hospitalisation, including 15 
patients that were admitted to an intensive care unit and nine that required ventilation 
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(McCrickard et al., 2017). The botulinum antitoxin was administered to 20 of the 31 
patients, and botulinum neurotoxin type A was detected in serum and stool samples. The 
“hooch” was reportedly prepared by combining honey, potatoes, apples and tomato paste 
in a plastic bag and allowing it to ferment for 3-5 days at room temperature, however the 
source of C. botulinum contamination remains unknown (McCrickard et al., 2017).  
The majority of outbreaks involving C. botulinum Group II are associated with home-cured 
meat and sausages, salted, dried or vacuum-packed fish, and home-made products 
prepared by the indigenous inhabitants of Alaska and Northern Canada, such as fermented 
seal flipper, salmon roe, beaver tail and muktuk (Peck, 2009). During the fermentation 
process of these homemade foods, botulinum neurotoxin (most often type E) can form. 
Toxin production can occur at a pH >5.0 or if fermentation takes place at temperatures 
greater than 3°C, i.e. during the soaking or early fermentation stage (Peck, 2014).  
 
1.2.3 Wound Botulism 
Wound botulism occurs when a wound is contaminated with spores of C. botulinum, which 
germinate to produce vegetative cells that form the botulinum neurotoxin. Infection at a 
wound site can lead to abscess formation, which is often caused by a variety of Clostridium 
species (Brett et al., 2004). The milieu of an abscess provides the ideal anaerobic 
environment to allow C. botulinum to thrive and as a result, wound botulism has become 
increasingly more common in drug abusers (Sobel, 2005). Black tar heroin is the most 
common form of heroin in Western United States due to the ease of which it can be 
sourced and as a result there is a strong positive correlation with wound botulism cases in 
California (Passaro et al., 1998). Injection of black tar heroin subcutaneously or 
intramuscularly, rather than directly into the veins, is referred to as “skin-popping” and 
results in abscess formation and skin devitalisation (Werner et al., 2000). Heroin is 
insoluble in water and thus, it is often dissolved in citric acid to make it suitable for 
injection, which damages the tissue surrounding the injection site and creates a favourable 
condition for spore germination and growth of C. botulinum (Brett et al., 2004, Sieradzan, 
2005). In the UK, there were 170 cases of wound botulism outlined in a Public Health 
England (PHE) report between 2000 and 2014, and all of these cases were attributed to 
injecting drug users (Public Health England, 2016). The majority of reported wound 
botulism cases that have been identified have been caused by C. botulinum Group I type A 
and B (Sieradzan, 2005). Clinically, wound botulism is indistinguishable from foodborne 
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botulism, apart from the absence of gastrointestinal symptoms. The incubation period for 
wound botulism is unknown as drug users often inject multiple times during a day (Sobel, 
2005). However, the incubation period for the onset of neurological symptoms of wound 
botulism unrelated to drug abuse has been reported to be between 4-13 days, compared 
to 6 hours-8 days in foodborne botulism (Hughes et al., 1981). 
 
1.2.4 Infant Botulism 
Infant botulism occurs when spores of C. botulinum are ingested by infants, usually less 
than 1 year old. The spores germinate and produce vegetative cells that are capable of 
forming the botulinum neurotoxin and temporarily colonise the infants’ colon due to their 
poorly developed gut microflora and lack of gastric acid (Arnon, 1980). Infant botulism is 
the most prevalent form of botulism encountered in the United States with approximately 
80-100 cases reported annually (Shapiro et al., 1998). A large epidemiological study in 
Japan and California revealed that there were 31 cases reported from 1986-2011 and 978 
cases reported from 1986-2010 in the two locations, respectively (Dabritz et al., 2014, Kenri 
et al., 2014). The main clinical manifestations of infant botulism are constipation, lethargy, 
muscle weakness, abnormal eye movements and poor feeding, progressing to flaccid 
paralysis and respiratory arrest if untreated (Long, 2007). The majority of infant botulism 
cases have been associated with botulinum neurotoxin serotype A and B, with type A 
occurring most commonly in Western United States and type B more prevalent  in Eastern 
United States (Paisley et al., 1995). C. botulinum spores are ubiquitous in the environment, 
however honey and dust have been found to be the main transmitters of the spores 
leading to infant botulism (Midura, 1996). The number of infant botulism cases related to 
the consumption of honey has been decreasing in the United States, due to a successful 
public awareness campaign communicating the potential risk of botulism. As a result, only 
approximately 20% of infant botulism cases are now associated with honey in the United 
States, compared to 59% of cases in Europe (Aureli et al., 2002). Infant botulism is rarer in 
the UK than in the USA and up until 2012, only 12 cases of infant botulism had been 
reported (Abdulla et al., 2012). Although the infant minimum infective dose of C. botulinum 
spores is not known, it has been hypothesised that as few as 10-100 spores in honey is 
sufficient to cause infant botulism (Arnon et al., 1979).  
In October 2003, the Food and Drug Administration approved the use of human botulism 
immune globulin (Baby-BIG) in cases of infant botulism. Plasma from adults that have been 
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immunised with pentavalent botulinum toxoid and that show a high concentration of 
antibodies able to neutralise botulinum neurotoxin type A and B are used in the 
development of Baby-BIG (Fox et al., 2005). A 5-year study by Arnon  et al. (2006) reported 
a significant reduction in the duration of hospital stays when cases of infant botulism were 
treated with Baby-BIG (2.6 weeks compared to 5.7 weeks), and also a reduction in the 
length of time mechanical ventilation and tube feeding was required by 3.2 and 6.4 weeks, 
respectively. Intravenous Baby-BIG has a half-life of approximately 28 days and a single 
dose is able to neutralise all botulinum toxin present in the bloodstream for at least 6 
months. The ability of the antitoxin to remain in the infant body for up to 6 months 
eradicates the potential issues of increased botulinum toxin absorption due to vegetative C. 
botulinum cell lyses, arising from antibiotics being administered to treat secondary 
bacterial infections (Johnson et al., 1979).  
 
1.3 Aetiology  
1.3.1 Regular neurotransmission at a synapse  
Neurotransmitters are endogenous chemicals capable of sending signals across a synapse 
from a neuron to a postsynaptic cell. Acetylcholine is a neurotransmitter that is synthesised 
from acetate and choline (Rossetto et al., 2014). Under resting conditions, 
neurotransmitters are synthesised in the neuronal cytosol and stored in the cytoplasm of a 
presynaptic nerve terminal (Jahn and Fasshauer, 2012). On arrival of an action potential at 
the distal nerve terminal, voltage-gated calcium channels open causing an influx of calcium 
ions. There are three proteins within the soluble group N-ethylmaleimide-sensitive factor 
attachment receptor (SNARE) proteins; synaptobrevin (a vesicle-associated membrane 
protein (VAMP)), syntaxin and synaptosome-associated protein SNAP-25, that assist with 
attaching vesicles containing acetylcholine to the cell membrane (Rossetto et al., 2014). 
Consequently, membrane-associated synaptotagins detect the increased concentration of 
calcium ions and become activated, leading to the association of three SNARE proteins 
responsible for docking, fusion and the release of vesicle contents into the synaptic cleft 
(Heidelberger, 2007). Degraded vesicle and membrane parts are recycled and reused to 
form new vesicles in the nerve terminal (Fagerlund and Eriksson, 2009). When an action 
potential arrives at the distal nerve terminal, many vesicles are released in synchrony 
creating a number of miniature endplate potentials. If the endplate potentials are large 
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enough to depolarise the muscle cell, then calcium will be released activating the actin-
myosin interaction, resulting in muscle contraction (Cohen-Cory, 2002). 
 
1.3.2 Mode of action of botulinum toxin   
C. botulinum neurotoxin serotypes A-G all interfere with the transmission of acetylcholine 
across the neuromuscular junction. The inhibition of acetylcholine release from the 
presynaptic nerve results in muscle paralysis, the main clinical manifestation of botulism 
(Burgen et al., 1949). The botulinum neurotoxin can act at different parts of the body that 
release acetylcholine, including the neuromuscular junction, autonomic ganglia (cluster of 
ganglion in the autonomic nervous system), postganglionic parasympathetic nerve endings 
and postganglionic sympathetic nerve endings (Sellin, 1985). Botulinum toxin binds to 
different gangliosides, such as synaptic vesicle-2 and synaptotagmin I/II, which then cleave 
the SNARE complex present in motor neurons. SNARE molecules normally function to 
mediate the fusion of the presynaptic plasma membrane with synaptic vesicles, initiating 
neurotransmitter release (Risselada and Grubmüller, 2012). The heavy chain (H) of the 
toxin binds irreversibly to receptors in the presynaptic neuron creating a toxin-receptor 
complex which is absorbed into the cell by endocytosis. Cleavage of the disulphide bonds 
between the heavy (H) and light (L) chains causes toxin to be released into the cytoplasm 
(Sellin, 1985, Stanley and Drachman, 1983). The light chain (L) of botulinum serotype A and 
E cleave SNAP-25 (a synaptosome-associated protein of 25kDa), serotype B, D, F and G 
cleave synaptobrevin (VAMP) and botulinum toxin type C cleaves both SNAP-25 and 
syntaxin (a plasma membrane anchored SNARE), preventing neurotransmitter release 
(Rossetto and Montecucco, 2008, Rummel et al., 2004).  
 
1.4 Uses of Botulinum Toxin 
1.4.1 Therapeutic  
The botulinum neurotoxin has been approved for use in treating a range of neurological 
and non-neurological disorders, mainly due its ability to inhibit neurotransmission at the 
neuromuscular junction (Gooriah and Ahmed, 2015). The Food and Drug Administration 
(FDA) has approved the use of botulinum serotypes A and B in the USA. The approved 
formulations of botulinum toxin type A are onabotulinumtoxinA (A/Ona; Allergan), 
abobotulinumtoxinA (A/Abo; Ipsen) and incobotulinumtoxinA (A/Inco; Merz 
Pharmaceuticals), or more commonly referred to as their brand names Botox®, Dysport® 
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and Xeomin®, respectively. The only botulinum B toxin that has been permitted for use in 
the USA is rimabotulinumtoxinB (B/Rima; Solstice Neurosciences), which is more commonly 
known as Myobloc®/ Neurobloc® (Hallett et al., 2013). In the late 1970s, botulinum toxin 
was first used in the treatment of strabismus (misalignment of the eyes) and since then, 
the FDA has approved its use for this condition and many others (Scott, 2004).  Cervical 
dystonia, characterised by involuntary contractions of cervical muscles, can be treated with 
botulinum toxin A after it was approved by the FDA in 2000, however treatment failure is 
reported in approximately 20% of patients due to optimal dosage and dosage interval 
discrepancies (Comella and Thompson, 2006).  Use of botulinum toxin type B can also be 
administered to treat cervical dystonia; however, it is usually only used if the patient shows 
resistance to botulinum toxin type A (Albanese et al., 2011).  
Abnormal contractions of the surrounding eye areas (blepharospasm) is a neurological 
condition often treated with botulinum toxin. In 1989, the FDA approved the 
administration of botulinum toxin type A as an injection into the orbicularis oculi muscle 
that functions to close the eyelids in order to treat blepharospasm (Hallett et al., 2013). 
Muscle stiffness (spasticity) resulting from a spinal cord injury, multiple sclerosis, cerebral 
palsy or a stroke can be treated with botulinum toxin A and B. A randomised-double blind 
study showed that patients improved by 92.3% after receiving botulinum toxin treatment 
in their upper arm after suffering from a stroke, compared to 50% in the placebo group 
(Childers et al., 2004).  Approximately 1-2% of the population is affected by chronic 
migraines, which can be defined as a headache lasting ≥ 15 days per month for ≥ 3 months 
(Jackson et al., 2012). The use of botulinum toxin A for the treatment of chronic migraines 
was discovered unintentionally through patients receiving cosmetic Botox®. The FDA and 
Medicine and Healthcare Product Regulatory Agency (MHRA) approved the use of 
botulinum toxin A for chronic migraines in 2010 in the USA and UK (Gooriah and Ahmed, 
2015). Hyperhidrosis is defined as the production of excess sweat from the axilla, palms, 
face and soles of the feet and has been shown to have serious social implications 
(Naumann et al., 2013). Intradermal or subdermal injection of botulinum toxin into the 
area of skin that is producing excess sweat can reduce axillary hyperhidrosis (Dressler, 
2012). Adverse effects have been reported with the use of botulinum neurotoxins (Table 1). 
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1.4.2 Biological Weapon  
Bioterrorism can be described as the intentional use of biological agents, such as bacteria, 
viruses or fungi, to cause deliberate harm to humans, animals or the environment 
(Greenfield et al., 2002). This can result in numerous victims in a short period and 
therefore, it is imperative that healthcare professionals are aware of the potential uses of 
biological agents as weapons (Keim and Kaufmann, 1999).  The Centers for Disease Control 
and Prevention (CDC) has classified microbial agents capable of being used as bioterror 
weapons into three groups; A, B and C. Multiple factors, such as mortality rate and 
dissemination ease, have enabled organisms and their toxins to be grouped into these 
three categories and category A agents pose the most threat, due to their fatality. Category 
A agents include variolar major (smallpox), Bacillus anthracis (anthrax), Yersinia pestis 
(plague), Fransicella tularensis (tularaemia), filoviruses including Ebola and Marburg 
haemorrhagic fever, arenaviruses including Lassa (Lassa Fever) and Junin (Argentine 
haemorrhagic fever) and C. botulinum neurotoxin (CDC, 2000). Botulinum neurotoxin was 
utilised during World War II by the Japanese and thereafter synthesised by the USA, USSR 
and Iraq for potential use as a biological weapon (Berger et al., 2016). The Japanese cult, 
Aum Shinrikyō, released aerosolised botulinum toxin at three sites in Japan between 1990 
and 1995, however all attempts failed reportedly due to erroneous microbial technique, 
internal sabotage or issues with aerosol-generating equipment (Tucker, 2000). Botulinum 
toxin still poses a threat to be used a biological weapon and hence, the CDC has a well-
established surveillance system in place to detect possible bioterrorism events (Shapiro et 
al., 1997).  
MEDICAL 
CONDITION 
TREATMENT  ADVERSE EFFECTS REFERENCE 
CERVICAL 
DYSTONIA 
Botulinum Toxin A 
and B 
Dysphagia, dry 
mouth, neck 
weakness 
(Comella and 
Thompson, 2006) 
BLEPHAROSPASM Botulinum Toxin A Ptosis, aggravated 
dry eyes, diplopia, 
lagophthalmos 
(Truong et al., 
2008) 
CHRONIC 
MIGRAINE 
Botulinum Toxin A Ptosis, muscle 
weakness, neck pain, 
neck stiffness 
(Jackson et al., 
2012) 
HYPERHIDROSIS Botulinum Toxin A Cold and flu-like 
symptoms, 
nonaxillary sweating 
(Naumann et al., 
2003) 
Table 1. Adverse effects resulting from the administration of botulinum toxin to treat a 
range of medical conditions. 
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1.5 Endospores  
1.5.1 Sporulation  
Endospore-forming aerobic and anaerobic bacteria, including C. botulinum, form 
endospores as a virulence mechanism in order to survive unfavourable conditions. Initially, 
the model organism for studying spore development was Bacillus subtilis, and this 
organism was one of the first Gram-positive bacteria to have its genome sequenced, 
however spore development follows a similar process in most endospore-forming bacteria 
(Henriques and Moran, 2007, Kunst et al., 1997). The initiation of sporulation due to 
nutrient depletion is evident in most Bacillus species, however there is some debate as to 
whether the same occurs in all Clostridium species (Dürre, 2005). Some Clostridium species 
initiate sporulation in response to an accumulation of end products of metabolism, e.g. 
Clostridium acetobutylicum, where the accumulation of acetone and butanol and a 
reduction in pH prompts sporulation (Dürre, 2005, Sauer et al., 1995).   
Sporulation of B. subtilis is initiated at the start of the stationary phase when nutrients are 
depleted. Histidine sensor kinases (KinA, KinB and KinC) are then activated resulting in the 
indirect phosphorylation of the transcription factor, Spo0A (a DNA-binding protein) via a 
multiple component phosporelay (Stephenson and Hoch, 2002). Asymmetrical division of a 
cell entering sporulation is initiated by the activation of Spo0A and σH (a sporulation 
specific sigma factor) and results in the production of two daughter cells in a structure 
termed a sporangium; a mother cell and a forespore (McKenney et al., 2013, Piggot and 
Hilbert, 2004). The mother cell then engulfs the forespore during a membrane fusion and 
migration process, similar to phagocytosis, during which the cortex, coat and other internal 
structures are developed.  The forespore advances into the mature endospore and the 
mother cell lyses to release the endospore after completion (Henriques and Moran, 2007).  
Sporulation in C. botulinum follows a similar process to B. subtilis; the endospore is formed 
due to asymmetric cell division, followed by engulfment of the forespore by the mother 
cell. The mother cell provides the forespore with the necessary structural properties to aid 
development of the mature spore and to maximise its survival (Errington, 2003). The spores 
are released into the environment when the mother cell lyses and remain metabolically 
inactive (Setlow, 2014). Spores can remain dormant in the environment for many years and 
can resist germicidal agents that usually kill non-endospore forming bacteria, such as 
chemical solvents, ionising radiation, high temperatures, detergents and hydrolytic 
enzymes (Nicholson et al., 2000). 
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1.5.2 Spore Structure and Function  
Spores of Bacillales and Clostridiales contain multiple similar concentric layers that form a 
spherical spore (Swick et al., 2016). The outermost layer of the spore is termed the 
exosporium (Figure 2a), which prevents large molecules from entering the spore. Although 
the exact  function of the exosporium is unknown, it may be involved in attachment and 
colonisation, because it is the surface layer of the spore that is exposed to the environment 
containing major spore surface antigens (Ball et al., 2008). It had been argued that some 
species of Bacillus, specifically B. subtilis, do not have an exosporium and instead have an 
exosporium-like layer which is a version of the outermost coat layer (Setlow, 2006). In 
contrast, spores of Bacillus megaterium and B. cereus contain an exosporium which is 
noticeably different to the spore coat in morphology (Manetsberger et al., 2015). The 
exosporium gene proteins in B. megaterium are encoded on a plasmid, which 
demonstrates that there is an association between plasmid-encoded genes and the 
formation of the exosporium in Bacillus species (Manetsberger et al., 2015). This work by 
Manetsberger et al. (2015) on B. megaterium was the first study to demonstrate this 
relationship in Bacillus species. Research on B. anthracis has established that the 
exosporium plays a major role in concealing epitopes in the spore coat, which would 
otherwise be recognised by macrophages in order to provide protection (Basu et al., 2007). 
The exosporium is comprised of specific proteins, carbohydrates and lipids, however the 
exact composition of the exosporium varies between different species and strains of 
endospore-forming bacteria (Henriques and Moran, 2007, Matz et al., 1970).  
The exosporium consists of a paracrystalline basal layer and external hair-like appendages, 
often termed the ‘hairy nap’, situated approximately 10-20nm from the coat surface in 
Bacillus cereus and B. anthracis (Beaman et al., 1972). Exosporium specific glycoproteins, 
such as the BclA protein in B. anthracis, contain a collagen-like repeat domain (CLR) which 
contributes to the formation of the hairy nap layer of the exosporium and is involved in the 
attachment and entry into the host, which influences spore surface proteins (Lequette et 
al., 2011, Sylvestre et al., 2003, Xue et al., 2011). In B. anthracis, the ExsY protein is 
essential for synthesising the exosporium, whereas in Clostridia the analogous proteins, 
BclA1 and CdeC, are required for the assembly of the coat and exosporium (Boydston et al., 
2006, Paredes-Sabja et al., 2014). The exosporium in C. sporogenes differs from the 
exosporium described in C. difficile, which lacks an inner coat space (Brunt et al., 2015, 
Paredes-Sabja et al., 2014). Limited information is available about the exosporium structure 
and function in C. botulinum, however researchers have found that in a C. botulinum Group 
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I type A strain the exosporium was arranged hexagonally and showed resistance to urea, 
dithiothreitol, sodium dodecyl sulfate and proteolytic enzymes (Masuda et al., 1980, 
Takumi et al., 1979).   
 
 
 
 
 
 
 
 
 
 
The spore coat (Figure 2b) is situated within the exosporium and is formed from a varying 
number of concentric layers, depending on the species of bacteria. B. subtilis features two 
coat layers, an inner and outer, and also a basement layer which forms between the inner 
coat and the cortex and the outer coat and the spore surface (Aronson et al., 1992). The 
inner layer of the coat is formed from between three and six lamellae and is approximately 
75nm wide in B. subtilis, whereas the outer layer consists of electron-dense striations 
which makes the structure thicker and it can measure up to 200nm wide in some species 
(Driks, 1999). The majority of the spore coat is made from soluble and insoluble protein, 
which constitutes approximately 50-80% of the total spore protein (Aronson and Fitz-
James, 1976, Pandey and Aronson, 1979). A hydrophilic protein, CotG, is abundant 
throughout the soluble portion of the spore coat and is a crucial protein in the 
development of the coat once another protein, CotB, has been incorporated into the 
mature spore (Sacco et al., 1995). A study by Donovan et al. (1987) revealed additional coat 
proteins, CotA, CotB, CotC and CotD, in the soluble fraction of B. subtilis coat which can be 
deleted without any dysfunction to the formation of the spore coat, however spores 
Figure 2. Schematic diagram of the spore structure in Bacillus and Clostridia (not drawn to 
scale) (Adapted from Setlow (2006)). N.B. only some species of Bacillus and Clostridia contain 
an exosporium.  
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lacking the CotD protein have been found to germinate less efficiently (Leggett et al., 
2012). The spore coat functions as an internal barrier to prevent large molecules, such as 
lysozyme, from accessing the spore cortex (Driks, 1999). Although a fraction of C. botulinum 
Group II spores are permeable to lysozyme following heat treatment (Peck et al., 1993). 
Molecules that are approximately 8kDa and 2kDa in size are able to pass thorough the 
spore coat in B. cereus and B. megaterium, respectively, which allows the passage of small 
molecular germinants to reach the germinant receptors in the spore inner membrane 
(Driks, 1999, Nishihara et al., 1989, Scherrer et al., 1971).  
The outer membrane (Figure 2c) is situated under the spore coat and is involved in spore 
formation (Piggot and Hilbert, 2004). The exact role of the outer membrane during 
sporulation is unclear, however studies have shown that it does not contribute to the 
spore’s heat, chemical or radiation resistance (Nicholson et al., 2000). The spore cortex 
(Figure 2d) is situated between the spore coat and germ cell wall, and is composed of 
peptidoglycan (Atrih et al., 1996). Spore peptidoglycan differs from the peptidoglycan in 
vegetative cells due to the substitution of approximately 50% of the disaccharides with 
muramic δ-lactam residues, at alternating positions (Atrih et al., 1996, Warth and 
Strominger, 1969, Warth and Strominger, 1972). In B. subtilis, vegetative cell wall 
peptidoglycan contains N-acetylglucosamine (NAG) and N-acetylmuramic (NAM) residues, 
which are cross-linked via peptide side chains to other glycan strands (Ghuysen, 1968, 
Warth and Strominger, 1971). However, in B. subtilis spore cortex peptidoglycan, 
approximately half of the NAM residues do not form peptide side chains with other glycan 
strands and as a result a cyclic muramic δ-lactam is formed (Warth and Strominger, 1972). 
The muramic δ-lactam structure is exclusive to spore cortex peptidoglycan, and therefore it 
may contribute to the spore’s dormancy and resistance properties (Popham, 2002).  
The germ cell wall (or primordial cell wall) (Figure 2e) is also composed of peptidoglycan, 
however as it transforms into the vegetative cell wall during outgrowth, the components 
differ from the peptidoglycan found in the spore cortex (Leggett et al., 2012). Degradation 
of the spore cortex during spore germination but not the germ cell wall results from the 
structural differences in cortex peptidoglycan and the germ cell wall. The muramic δ-lactam 
in cortex peptidoglycan, which are not present in germ cell wall peptidoglycan, acts as a 
substrate for specific cortex-lytic enzymes (autolysins), which degrade the cortex of the 
spore (Atrih et al., 1998). The inner membrane (Figure 2e) provides the spore core with 
protection and is the final barrier that prevents harmful molecules from reaching the spore 
core (Setlow, 2006, Zheng et al., 2016). After germination, the inner membrane develops 
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into the plasma membrane of the vegetative cell during outgrowth (Zheng et al., 2016). The 
lipid composition of the inner membrane of a B. megaterium spore is similar to the 
vegetative plasma membrane; however, the protein configuration is remarkably different 
(Griffiths and Setlow, 2009). The spore’s inner membrane contains germinant receptors 
and SpoVA protein channels, which are absent from vegetative cells (Setlow, 2003).  
The spore core (Figure 2f) retains the spore’s DNA and metabolic components of the cell 
(Atrih and Foster, 2002). The spore core is dehydrated, which contributes to spore 
dormancy. Dependent on the species, ~27-55% of the total wet weight of the spore core is 
made up of water, compared to 75-80% in a growing cell (Gerhardt and Marquis, 1989). As 
a result, the amount of free water available in the spore core is minimised, which restricts 
the movement of large molecules for enzymatic action (Cowan et al., 2003). The spore core 
also contains dipicolinic acid (pyridine-2,6-dicarboxylic acid, DPA), which is synthesised in 
the mother cell compartment during sporulation  (Setlow, 2006). In Bacillus and Clostridium 
species, approximately 5-15% of the total dry weight of the spore contains DPA, which can 
combine with divalent cations, such as Ca2+,, to form a 1:1 chelate (CaDPA) (Gerhardt and 
Marquis, 1989).  
 
1.5.3 Germination  
Germination is the process by which dormant spores advance to vegetative cells, via the 
process of outgrowth (Setlow, 2003). Germination in the model organism, B. subtilis, is well 
documented; however, less is understood about the germination mechanisms involved in 
Clostridium species, including C. botulinum (Setlow, 2014). Recently, the germination 
pathways in C. botulinum Group I and II have been proposed by Brunt et al. (2016), and this 
analysis provided the first insight into the differences in germination between these two 
groups. Germination is activated by the presence of strain and species-specific nutrient 
germinants that have a low molecular weight, such as amino acids and some sugars 
(Paredes-Sabja et al., 2011). Spores can also germinate in response to non-nutrient 
germinants, such as lysozyme, CaDPA and dodecylamine (a cationic surfactant) (Gould, 
1969). The germinant receptors in B. subtilis are encoded by gerA, gerB and gerK homolog 
operons, composed of three protein subunits (A, B and C) located in the inner membrane 
of the spore in a tricistronic operon (termed gerA operon homologs) (Brunt et al., 2014, 
Igarashi et al., 2004). Homologous GerA proteins have been found in other Bacillus species 
and in some Clostridium species (Brunt et al., 2014, Moir et al., 2002, Paidhungat and 
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Setlow, 2002). Proteins A and B are integral membrane proteins, whereas protein C is a 
peripheral lipoprotein anchored to the membrane via a diacylglycerol chain (Igarashi et al., 
2004). 
The germinant receptor GerA requires all proteins to be intact for germination to proceed, 
whereas GerB and GerK can function with only GerBA and GerBC, and GerKC present, 
respectively. In B. subtilis, the germinant L-alanine is recognised by the GerA receptor 
(Paidhungat and Setlow, 2000). As described earlier the spore coat functions as a sieve to 
allow small molecular germinants to penetrate through the coat and gain access to the 
inner membrane (Moir and Cooper, 2015). A recent study on B. anthracis revealed that the 
absence of GerP in the spore coat reduces the efficiency of nutrient germinant stimulated 
germination and suggested that the proteins encoded by the gerP operon affect spore coat 
permeability (Carr et al., 2010) . B. megaterium, a bacterium often found in soil and named 
due to its large size, is relatively distinct from other members of the Bacillus genus, 
especially B. subtilis and B. cereus (Eppinger et al., 2011, Ramirez-Peralta et al., 2013). 
There are six germinant receptor operons within the B. megaterium genome and gerU (a 
plasmid-borne operon) has been identified as the tricistronic operon that triggers 
germination in response to glucose, leucine, proline and some inorganic salts (Christie and 
Lowe, 2007, Christie et al., 2010a). A recent study by Brunt et al. (2014) has indicated 
germinant receptors in C. botulinum and C. sporogenes are composed of three protein 
subunits (A, B and C), according to the GerX subtype. C. botulinum Group I possess three 
germinant receptor types (GerX1, GerX2 and GerX3), whereas, C. botulinum Group II only 
has one class of germinant receptor (GerX3) (Brunt et al., 2016). 
The mechanism by which germinant receptors are activated by nutrient/ non-nutrient 
germinants is not fully understood, however it has been proposed that a conformational 
change happens to the protein when a germinant binds (Moir and Cooper, 2015). In C. 
botulinum Group I and its closely related surrogate, C. sporogenes, germinant receptors are 
activated by a combination of amino acids with L-lactate/ NaHCO3, however some studies 
have reported variable effects of using L-lactate/ NaHCO3 (Broussolle et al., 2002). In 
contrast, the addition of L-lactate as a germinant is essential for germination of C. 
botulinum Group II strains (Plowman and Peck, 2002). One study in particular has reported 
that C. botulinum Group I and C. sporogenes germinated in the presence of L-alanine, 
suggesting that these species may have a GerA germinant receptor, or another homologous 
receptor that is activated by L-alanine, similar to the germinant receptor that binds L-
alanine in B. subtilis (Broussolle et al., 2002). Amino acid stimulated germination in C. 
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botulinum Group I strain ATCC3502 requires two type 1 GerXA germinant receptors (Brunt 
et al., 2014). On receipt of a germinant and the initiation of a signal transduction, the spore 
is committed to germinate and cannot revert to dormancy, even after the removal of the 
germinant (Stewart et al., 1981).  
During stage I of germination in B. subtilis, cations (H+ and Zn2+) are excreted from the 
spore core, resulting in an increase in pH from ~6.5- 7.7 which aids 3-phosphoglycerate 
metabolism, generating ATP (Nerandzic and Donskey, 2010). Then, a large portion of a 1:1 
chelate of CaDPA in the spore core is released via SpoVA channels, which in turn causes an 
influx of water to the spore core contributing to the loss in heat resistance (Li et al., 2012). 
The SpoVA proteins, specifically SpoVAD, function to package CaDPA during sporulation 
and create a mechanosensitive channel in which this large store of CaDPA can be expelled 
from the spore core during germination (Li et al., 2012). Three SpoVA proteins have been 
identified, however, the mechanism by which these proteins interact with each other and 
their surrounding proteins is still poorly understood (Brunt et al., 2016). During the second 
stage of germination in B. subtilis, cortex lytic enzymes, CwlJ and SleB, initiate 
peptidoglycan degradation in the spore cortex (Fukushima et al., 2002, Popham et al., 
1996). Cortex lytic enzymes are located in different parts of the spore; CwlJ is synthesised 
in the mother cell and confined in the spore by YwdL (GerQ) (spore coat protein), whereas, 
SleB is synthesised in the forespore during sporulation and is situated in both the inner and 
outer membrane in association with the protein YpeB (Chirakkal et al., 2002, Ragkousi et 
al., 2003). There is also evidence in B. anthracis, that another cortex lytic enzyme SleL is 
involved in further degrading large fragments of peptidoglycan produced by CwlJ and SleB, 
so that they are small enough to pass through the spore coat (Lambert and Popham, 2008). 
The main cortex lytic enzyme involved in germination of B. megaterium strain QM B1551 is 
the outcome of transglycosylation relating to SleB lytic activity (Christie et al., 2010b). 
However, in the absence of the cortex lytic enzymes CwlJ and SleB, germination in B. 
megaterium can still proceed due to the presence of SleL (an N-acetylglucosaminidase), 
which initiates degradation of the spore cortex during the second stage of germination 
(Üstok et al., 2014, Üstok et al., 2015). Spores of some Clostridium species also contain the 
cortex lytic enzymes CwlJ and SleB, whereas spores of C. difficile, C. perfringens and C. 
botulinum Group II contain the cortex lytic enzyme SleC, which hydrolyses peptidoglycan 
and is required for germination (Miyata et al., 1995, Setlow, 2003). The breakdown of the 
cortex results in the complete rehydration and swelling of the spore core, which stimulates 
the inner membrane proteins and lipids to become mobile, terminating spore dormancy 
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(Moir and Cooper, 2015). Many other spore formers, including C. perfringens follow a 
similar germination pathway to B. subtilis, in which CaDPA release is followed by cortex 
hydrolysis, however, this process is reversed in C. difficile as cortex hydrolysis precedes 
CaDPA release (Francis et al., 2015, Paidhungat et al., 2001). In C. botulinum Groups I and II, 
it is still unknown whether CaDPA release precedes or follows cortex hydrolysis (Figure 3) 
(Brunt et al., 2016). 
 The germination mechanisms in C. botulinum are still poorly understood, however, by 
gathering information from a variety of sources relating to B. subtilis and C. perfringens, 
and from experimental data, the germination pathways in C. botulinum Group I and II have 
recently been proposed for the first time (Figure 3) (Brunt et al., 2016). Strains of C. 
botulinum Group I follow a similar germination pathway to B. subtilis; germinant receptors 
recognise nutrient germinants, CaDPA is released through SpoVA channels, cortex lytic 
enzymes (CwlJ and SleB) are activated, the cortex is hydrolysed via peptidoglycan cleavage, 
the coat and membrane is degraded, resulting in the initiation of lipid and protein 
metabolism and finally cell outgrowth occurs. Spores of C. botulinum Group II follow a 
germination pathway more similar to C. perfringens; nutrient germinants are recognised by 
their corresponding germinant receptors, CaDPA is released via SpoVA channels and the 
cortex lytic enzyme (SleC) is activated by the protein CspB. Afterwards, the cortex is 
hydrolysed and then membrane and coat degradation occurs, resulting in macromolecule 
metabolism and cell outgrowth (Figure 3) (Brunt et al., 2016). The genes required for cell 
outgrowth are equivalent to those required in vegetative cell growth (Murray et al., 1998, 
Nessi et al., 1995). 
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1.6 Experimental Rationale  
To further understand the proposed germination pathways in C. botulinum Group I and II, a 
selection of nutrient and non-nutrient germinants have been used that act on different 
parts of the spore. Nutrient germinants, such as L-alanine, activate the germinant receptors 
located in the spore’s inner membrane (Brunt et al., 2014). A range of amino acid 
germinants, including L-alanine and L-cysteine have been shown to germinate C. botulinum 
Group II (Plowman and Peck, 2002). Using this combination of germinants, germination 
occurred within six hours and resulted in ≥ 90% phase dark spores at 20°C (Plowman and 
Peck, 2002). Spores of C. botulinum Group I can be triggered to germinate with L-alanine/L-
lactate or L-cysteine/L-lactate in the presence of a neutral buffer, such as Tris-HCl (pH 7.0) 
containing NaHCO3 (Rowley and Feeherry, 1970). The study by Plowman and Peck (2002) 
demonstrated that L-cysteine and L-alanine were the germinants that induced the most 
rapid germination in C. botulinum Group II, and therefore these amino acids have been 
selected as the nutrient germinants for both strains of C. botulinum in the present study. 
Figure 3. Proposed germination pathways in C. botulinum Group I and II. It is presently 
unknown whether cortex hydrolysis and core hydration precedes or follows CaDPA
 
release 
(Adapted from Brunt et al. (2016)). 
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DDA induces CaDPA release and cortex degradation in spores of B. subtilis. In a previous 
study, spores lacking CwlJ, SleB or both cortex lytic enzymes germinated successfully with 
DDA, indicating that DDA does not act directly on the cortex lytic enzymes to initiate 
germination (Paidhungat and Setlow, 2002). DDA may germinate spores by altering the 
spore’s inner membrane properties, suggesting that DDA acts on SpoVA channels 
responsible for packaging (during sporulation) and release (during germination) of CaDPA 
(Setlow et al., 2003). Exogenous CaDPA has been shown to germinate spores of B. subtilis 
by activating the CwlJ protein (Paidhungat et al., 2001). Germination with lysozyme 
bypasses germinant receptors and cortex lytic enzymes, and directly hydrolyses the spore 
cortex initiating spore germination (Vepachedu and Setlow, 2007). A study by Peck et al. 
(1992a) demonstrated that spores of C. botulinum Group II strain Eklund 17B are damaged 
by heating at 85°C for 1 minute and can be recovered by lysozyme. Using the germinants 
mentioned, it is possible to dissect the proposed germination pathway in C. botulinum 
Groups I and II to determine which part of the spore is damaged by heat (Figure 4). 
Understanding the mechanisms involved in spore germination can improve the control of 
botulinum neurotoxin forming Clostridia. Knowledge of how spore germination can affect 
food safety will be beneficial to industry and may contribute to a greater effort to enable 
consumer demands for novel foods (e.g. more fresh-like minimally processed) to be 
realised. 
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1.7 Aims  
The formation of highly resistant spores is one reason that C. botulinum Groups I and II are 
dangerous pathogens, with the other major reason being the ability to form the highly 
potent botulinum neurotoxin during growth of vegetative cells. Spore germination is the 
key step connecting spores to neurotoxin-forming vegetative cells. The aim of this study is 
to evaluate the proposed germination pathways in C. botulinum Group I and II as described 
by Brunt et al. (2016), by using a range of physiological techniques. The effect of heat on 
the germination apparatus of C. botulinum Group I and II will be evaluated by heating to 
95°C and 85°C, respectively. The timing of CaDPA release from the spore core is presently 
unknown in C. botulinum, and techniques outlined in a recent paper by Francis et al. (2015) 
will be used to determine whether CaDPA release precedes or follows cortex hydrolysis.  
Figure 4. Proposed germination pathways in C. botulinum Group I and II, showing the 
input of nutrient and non-nutrient germinants and the position they act upon to induce 
germination. It is unknown whether cortex hydrolysis and core hydration precedes or 
follows CaDPA
 
release (Adapted from Brunt et al. (2016)). 
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2. Materials & Methods  
2.1 Preparation of spores 
C. botulinum Group I strain Af84 was isolated from soil in Argentina in 1966 and forms 
three botulinum neurotoxins (subtypes A2, F4, F5). C. botulinum Group II strain Eklund 17B 
was isolated from Pacific sediments in 1965 and forms one botulinum neurotoxin (subtype 
B4). C. botulinum Group I strain Af84 and Group II strain Eklund 17B were grown on PYGS 
(peptone-yeast-glucose-starch) (Oxoid) agar at 30°C overnight in an anaerobic cabinet (Don 
Whitley) containing CO2:H2:N2 (5:10:85). Colonies formed on PYGS agar were used to make 
a Microbank™ (Pro-Lab Diagnostics) bead stock, and stored at -80°C until required. To grow 
C. botulinum from the bead stock, one Microbank™ bead of Group I strain Af84 and Group 
II strain Eklund 17B was transferred to a 20ml Robertson’s Cooked Meat broth (Southern 
Group Laboratories) that had been reduced by heating for 15 minutes at 100°C prior to 
bead inoculation and subsequent incubation at 30°C overnight in an anaerobic cabinet. 
Spores of Group I Strain Af84 and Group II strain Eklund 17B were produced in tissue 
culture flasks (Helena Biosciences) containing 40ml Cooked Meat Medium. Cooked Meat 
Medium was prepared by macerating Robertson’s Cooked Meat broth, using an Omni 2000 
tissue homogeniser (Camlab), and adding 15g agar per litre (Oxoid) and 1g glucose per litre 
(Fisher Chemical). Tissue culture flasks were inoculated with 3ml of an overnight culture of 
each strain grown in Robertson’s Cooked Meat broth. Inoculated tissue culture flasks were 
incubated at 30°C in an anaerobic cabinet for one week. Spores were harvested with 20ml 
sterile ultra-pure water and approximately eight glass beads (per flask) and transferred to 
sterile 50ml centrifuge tubes. The spore suspension was centrifuged (SorvallTM) (12000g, 15 
minutes, 4°C) and the supernatant discarded, leaving a pellet. The pellet was resuspended 
in 1ml sterile ultra-pure water, vortexed and washed (12000g, 15 minutes, 4°C) three times 
with 20ml sterile ultra-pure water. After the final wash, the pellet was resuspended in 2ml 
sterile ultra-pure water. Spores were purified using 50% concentration Gastrografin (Bayer) 
by centrifugation (8000g, 60 minutes, 4°C). The resultant spore pellet was washed three 
times with 20ml water (10000g, 15 minutes, 4°C). Clean spore suspensions consisted of 
>95% phase-bright spores, as determined by visual assessment of approximately ten fields 
of view using phase contrast microscopy at 40x magnification (Zeiss). Spores were diluted 
with sterile ultra-pure water to an optical density (OD600) of ~0.5 and stored at 4°C until 
required. Purity checks were performed by inoculating spores crops onto PYGS agar plates 
and Reinforced Clostridial Medium containing 5% (w/v) skimmed milk and incubated at 
30°C overnight in an anaerobic cabinet. 
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2.2 Assessing the inhibitory effect of lysozyme on growth from spores of C. 
botulinum Group I and II  
PYGS agar was prepared in individual Duran bottles and sterilised by autoclaving (121°C/15 
minutes). A 10mg/ml stock solution of Chicken Egg White Lysozyme (Sigma-Aldrich) was 
prepared in ultra-pure water and filter sterilised using a 0.22µm filter (Sartorius Stedim). In 
a Laminar flow cabinet (Wolf Laboratories), differing amounts of the stock solution of 
lysozyme were added to the liquid PYGS to a final concentration of 0, 1, 3, 10, 30 and 
100µg/ml of lysozyme. Each PYGS/lysozyme solution was poured into individual triple vent 
petri dishes (Thermo-Fisher) and transferred to separate anaerobic cabinets set to a 
temperature of 30°C and 37°C to reduce overnight. Spores of Group I strain Af84 and Group 
II strain Eklund 17B were serially diluted (100-10-5) in saline (0.85%) and 100µl of the final 
dilution of each strain was spread onto each agar plate at each lysozyme concentration 
using a sterile L-shaped spreader (Thermo-Fisher), in triplicate. Inoculated plates were 
incubated at 30°C for strain Eklund 17B and 37°C for strain Af84 for 2 days. Colonies were 
enumerated after 2 days, and the viable count calculated for each concentration of 
lysozyme.  
 
2.3 Preparation of germinant solutions   
Tris-HCl (20mM, pH 7.4) (Sigma-Aldrich) buffer was prepared and supplemented with 
100mM NaHCO3 (Fisher Scientific) and 100mM Sodium L-lactate (Melford). A control buffer 
was prepared containing only Tris-HCl (20mM, pH 7.4) buffer. The nutrient germinants L-
alanine (50mM) and L-cysteine (50mM) were prepared in Tris-HCl (20mM, pH 7.4) buffer, 
supplemented with NaHCO3 (100mM) and Sodium L-lactate (100mM). A 1.2mM solution of 
dodecylamine (DDA) (Sigma- Aldrich) was prepared by adding 10mg of crystalline solute to 
50ml sterile ultra-pure water and heating at 55°C in a hybridisation oven overnight to allow 
DDA to dissolve. DDA was stored at 55°C and used within one week. For germination with 
CaDPA (60mM), a 120mM stock of 2,6-Pyridinedicarboxylic acid (DPA) (Sigma-Aldrich) was 
prepared and adjusted to pH 8.0-8.3 using Tris Base (Sigma-Aldrich) and a 120mM solution 
of CaCl2 (Sigma-Aldrich) was prepared in 30ml water. A 10µg/ml stock of chicken egg white 
lysozyme (Sigma-Aldrich) was prepared in Tris-HCl buffer (20mM, pH 7.4). Each germinant 
solution was filter sterilised (0.22µm filter) and freshly prepared for each experiment.  
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2.4 Germination assay measuring change in optical density  
Spores of strain Af84 and strain Eklund 17B were heat activated in a water bath for 15 
minutes at 80°C and 60°C, respectively, and held on ice before use within one hour. The 
effect of various nutrient and non-nutrient germinants on spore germination was measured 
using a Bioscreen C analyser system (Labsystems) to measure the fall in OD600. Amino acid 
germinant (50µl), L-alanine or L-cysteine, was dispensed into a well of a honeycomb plate 
(Steri) and then 50µl of spore suspension added (OD600 ~0.5). Each test was performed in 
triplicate. Controls containing Tris-HCl (20mM, pH 7.4) buffer and spores of each strain 
were also added in the same volumes. The Bioscreen was positioned inside an anaerobic 
cabinet and the temperature set to 30°C. For germination of spores with DDA, 1ml of 
1.2mM DDA was combined with 30µl potassium phosphate buffer (1M, pH 7.6) and stored 
at 45°C, DDA/potassium phosphate  solution (100µl) was added to wells containing 10µl 
spores (OD600 ~ 0.5). Each test was performed in triplicate and the temperature set to 45°C. 
CaDPA (90µl, 60mM) was added to wells before the addition of a 10µl spore suspension 
(OD600 ~ 0.5) of each strain and the temperature was set to 30°C or to 45°C. Controls 
containing Tris-HCl (20mM, pH 7.4) buffer and spores of each strain were also added in the 
same volumes. Germination of spores with lysozyme (10µg/ml) was performed using 50µl 
of lysozyme (10µg/ml) with 50µl (OD600 ~ 0.5) spores of each strain, in triplicate. Controls 
containing Tris-HCl (20mM, pH 7.4) buffer and spores of each strain were also added in the 
same volumes. The Bioscreen was used inside an anaerobic cabinet and the temperature 
was set to 37°C. Spore germination with lysozyme (10µg/ml) was also determined using a 
haemocytometer (C-Chip™, Digital Bios). The number of spores present in 20 squares was 
enumerated at the beginning of the experiment and after 24 hours of incubation with 
lysozyme (10µg/ml). 
At the end of all germination experiments, a 5µl sample from each well was examined by 
phase-contrast microscopy (Zeiss, 40x magnification) to estimate the extent of 
germination.  
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2.5 Germination assay monitoring percentage of phase-dark spores  
A separate experiment was performed with L-alanine, L-cysteine and CaDPA using screw-
cap tubes (2ml) in the same ratio of germinant to spores as used in Bioscreen experiments, 
and the conditions reflected those used during germination experiments. Samples (5µl) 
were taken every 10 minutes during the first hour for C. botulinum Group II and then hourly 
thereafter, and every hour for C. botulinum Group I. The percentage of phase-dark spores 
was estimated by visual representation of 10-fields of view using phase-contrast 
microscopy (40x magnification).  
 
2.6 Removal of spore coats using dithiothreitol 
Spore coats were removed prior to incubation with lysozyme, CaDPA or DDA for 
germination experiments. For removal of spore coats, spore crops were harvested by 
centrifugation (12000g, 15 minutes, 4°C), resuspended in 0.2ml sterile ultra-pure water and 
added to 1.6ml of decoating solution. The decoating solution was prepared by combining 
1% SDS (Sigma-Aldrich), 0.1M 1,4-dithiothreitol (Sigma-Aldrich), 0.1M NaCl (Sigma-Aldrich), 
pH 10 (adjusted with 2M NaOH) (Sigma-Aldrich). The spore/decoating solution was then 
placed in a 37°C incubator and shaken at 30 minute intervals for two hours. The spores 
were harvested by centrifugation (12000g, 15 minutes, 4°C), washed three times in 20ml 
sterile ultra-pure water (12000g, 15 minutes, 4°C) and diluted with sterile ultra-pure water 
to an OD600 ~0.5. Decoated spore suspensions were stored at 4°C and used within 48 hours 
of preparation.  
 
2.7 Removal of spore coats using sodium thioglycolate  
A 2M solution of sodium thioglycolate (Sigma-Aldrich) was prepared in ultra-pure water 
and adjusted to pH 10.0 with 6N NaOH (Sigma-Aldrich). The decoating solution was filter 
sterilised (0.22µm filter) and prepared fresh for each experiment. To decoat spores of 
Group I strain Af84 and Group II strain Eklund 17B, 5ml of sodium thioglycolate solution 
was added to the spore pellet (OD600 ~0.5) and incubated at 45°C for 30 minutes. The 
decoated spores were then harvested and washed three times with 20ml sterile cold ultra-
pure water using a centrifuge (15000g, 15 minutes, 4°C) and the spore pellet was 
resuspended in 100µl sterile ultra-pure water. Sodium thioglycolate decoated spores were 
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used in heat inactivation and recovery experiments with lysozyme, DDA and L-alanine. 
Spores were decoated prior to each experiment and used within one hour. 
 
2.8 Thermal death of spores of C. botulinum Group I strain Af84 and Group II 
strain Eklund 17B 
The submerged tube method was used to determine the thermal death of Group I strain 
Af84 and Group II strain Eklund 17B, essentially according to Peck et al. (1992). Sorenson’s 
phosphate buffer (9.9ml, pH 7.0, 67mM) was dispensed into HACH tubes and sterilised by 
autoclaving (121°C, 15 minutes). The HACH tubes containing Sorenson’s buffer solution 
were submerged in a water bath at 95°C and 85°C for Group I and II, respectively.  When 
the temperature in the water bath reached 95°C (Group I) and 85°C (Group II), 100µl of 
spores (OD600 ~ 0.5) of Group I strain Af84 or Group II strain Eklund 17B was added to each 
tube using a Gas Tight Hamilton syringe and 21Gx 1.5” needle (Terumo). 
For Group I strain Af84 the tubes were removed at 1, 2, 3, 4, and 6 hours after spore 
inoculation and plunged into ice. Controls contained 100µl unheated spores and 9.9ml 
Sorenson’s phosphate buffer (pH 7.0, 67mM). After each time point, the heated spore 
suspension was serially diluted (100-10-5) in saline (0.85%), and 100µl of each dilution was 
spread onto PYGS plates (in triplicate). The plates were incubated for 1 week at 30°C in an 
anaerobic cabinet and the number of colonies formed was counted daily. The experiment 
was repeated at 85°C with Group II strain Eklund 17B at 0, 1, 2, 5, 10 and 20 minutes. 
 
2.9 Heat Inactivation and decoating of spores  
Spores were heat inactivated by inoculating two HACH tubes containing 9.9ml Sorenson’s 
phosphate buffer (pH 7.0, 67mM) with 100µl spores (OD600 ~0.5), following the submerged 
tube method as above. Each set of tubes were heated for 4 hours at 95°C for C. botulinum 
Group I strain Af84 and 2 minutes at 85°C for C. botulinum Group II strain Eklund 17B. Two 
unheated HACH tubes containing 9.9ml Sorenson’s phosphate buffer (pH 7.0, 67mM) were 
also injected with 100µl spores of each strain (OD600 ~0.5) as a control. Heat treated and 
control samples were transferred to a 15ml Falcon tube and centrifuged (1558g, 15 
minutes, 4°C).  
To decoat spores using dithiothreitol, spore pellets were resuspended in 200µl ultra-pure 
water and 1.6ml dithiothreitol decoating solution was added. The spore suspension was 
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incubated at 37°C for 2 hours, shaking every 30 minutes to remove spore coats. Following 
incubation, spores were harvested by centrifugation (1558g, 15 minutes, 4°C) and the 
resulting pellet was washed three times with 1ml ultra-pure water (1558g, 15 minutes, 
4°C). The spore pellet was resuspended in 100µl ultra-pure water to an OD600 ~0.5 and re-
inoculated into a fresh HACH tube containing 9.9ml Sorenson’s phosphate buffer (pH 7.0, 
67mM).  
To decoat spores using sodium thioglycolate, the heat inactivation process was the same 
and 5ml decoating solution was added to the resulting spore pellet after harvesting 
(15000g, 15 minutes, 4°C). Tubes were incubated at 45°C for 30 minutes and washed three 
times with 20ml cold ultra-pure water (15000g, 15 minutes, 4°C). The spore pellet was 
resuspended in 100µl ultra-pure water and inoculated into new HACH tube containing 
Sorenson’s phosphate buffer (pH 7.0, 67mM). 
 
2.10 Recovery of heat inactivated spores with lysozyme  
Heat inactivated and unheated spore suspensions (coated or decoated) of both strains 
were serially diluted (100-10-5) in saline (0.85%) and spread onto PYGS plates and PYGS 
plates containing lysozyme (10µg/ml), in triplicate. Plates of Group II Eklund 17B strain 
were incubated at 30°C and plates of Group I strain Af84 were incubated at 37°C in an 
anaerobic cabinet. Colonies were enumerated after 2 day incubation and the viable count 
(CFU/ml) determined.  
 
2.11 Recovery of heat inactivated spores with L-alanine  
To determine whether a nutrient germinant could recover heat inactivated spores of C. 
botulinum Group I strain Af84 and Group II strain Eklund 17B, spores were plated on PYGS 
plates, supplemented with 50mM L-alanine. Spores were heat inactivated as above, and 
coated and decoated spores were plated onto PYGS plates and PYGS plates containing 
50mM L-alanine. Plates of Group II Eklund 17B strain were incubated at 30°C and plates of 
Group I strain Af84 were incubated at 37°C in an anaerobic cabinet. Colonies were 
enumerated after 2 day incubation and the viable count (CFU/ml) determined.  
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2.12 Recovery of heat inactivated spores with dodecylamine  
After heat inactivation and decoating of spores by either dithiothreitol or sodium 
thioglycolate, an aliquot (50µl) of spores (decoated and coated) was incubated with 1.03ml 
of 1.17mM DDA and 30mM of potassium phosphate solution overnight at 45°C. The DDA 
treated samples were washed three times with 1ml sterile ultra-pure water in a centrifuge 
(12000g, 4°C, 10 minutes) and resuspended in the original volume (50µl) with sterile ultra-
pure water. All 50µl treatment samples were diluted (one in ten) with Sorenson’s 
phosphate buffer (pH 7.0, 67mM) and serially diluted in saline (0.85%) (100-10-5). An aliquot 
(100µl) of each sample was spread onto PYGS plates and incubated for two days at 37°C or 
30°C for Group I and Group II, respectively. After two days of incubation, the plates were 
enumerated and the viable count (CFU/ml) determined. The PYGS plates remained in the 
anaerobic cabinet for a maximum of seven days and were checked periodically to measure 
any increase in number of colonies formed.  
A minimum detection limit for calculating the viable count was set at less than five colonies 
per plate for all experiments. 
 
2.13 Monitoring CaDPA release using Terbium Fluorescence 
 To produce a calibration curve for DPA fluorescence, a 20µm and 200µm stock of DPA was 
prepared (see above). A 1600µM stock of Terbium (III) Chloride (TbCl3) (Sigma-Aldrich) was 
also prepared in sterile ultra-pure water. Wells of an opaque 96-well plate (Thermo 
Scientific) were filled with 100µl of the following concentrations of DPA (µM); 0, 1, 2, 3, 4, 
5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 (diluted with Tris-HCl, 20mM, pH 7.4). To 
each well, 100µl TbCl3 (1600µM) was added to give a final concentration in each well of 
800µM. Fluorescence was measured using a FLUOstar Omega plate reader (BMG Labtech) 
(excitation, 230nm; emission, 550nm; measurement start time, 0.5; flashes per well, 20; 
positioning delay, 0.5s; top optic used). 
CaDPA release from spores of C. botulinum was measured using terbium fluorescence, 
essentially according to Francis et al. (2015). A 50mM germinant solution of L-alanine was 
prepared in Tris-HCl buffer (20mM, pH 7.4), supplemented with 100mM NaHCO3 and 
100mM Sodium L-lactate, as described above. A control solution was prepared which 
contained only Tris-HCl buffer (20mM, pH 7.4). Spores were adjusted to an OD600 of ~60 
and heat activated for 15 minutes at 80°C and 60°C, for Group I and II respectively, then 
cooled on ice. Wells of an opaque 96-well plate (Thermo Scientific) contained 115µl 50mM 
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L-alanine germinant solution and 10µl 800µM Terbium (III) Chloride. To each well, 5µl of 
heat activated spores were added and mixed by aspiration. Controls included 800µM TbCl3 
with spores (no germinant), and L-alanine with TbCl3 only (no spores). CaDPA release was 
monitored at 25°C for 24 hours using a FLUOstar Omega fluorescence plate reader (BMG 
Labtech) (excitation, 230nm; emission, 550nm; measurement start time, 0.5; flashes per 
well, 20; positioning delay, 0.5s; top optic used). At the end of the experiment, a 5µl sample 
was taken from each set of three wells and observed under phase-contrast microscopy for 
presence of phase bright or phase dark spores as outlined above.  
 
2.14 Quantifying the DPA content per spore of C. botulinum Group I strain Af84 
and Group II strain Eklund 17B  
The concentration of spores of strain Af84 and strain Eklund 17B was determined, using a 
haemocytometer, to estimate the number of spores present in a 10μl sample. A 
concentrated suspension of spores of each strain was serially diluted (1/10) from the 
original concentration to 100 using sterile ultra-pure water. Dilutions were autoclaved for 
15 minutes at 121°C, and cooled on ice. Wells of an opaque 96-well plate were filled with 
1600μM TbCl3 and 100µl of autoclaved spores of each strain to give a final TbCl3 
concentration of 800μM. Wells containing various concentrations of DPA and TbCl3 were 
also included in the same plate as a calibration curve for quantifying DPA concentration. 
Fluorescence intensity was read using a FLUOstar Omega fluorescence plate reader (BMG 
Labtech) (excitation, 230nm; emission, 550nm; measurement start time, 0.5; flashes per 
well, 20; positioning delay, 0.5s; top optic used). 
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3. Results  
3.1 Thermal death of spores of C. botulinum Group I strain Af84 and Group II 
strain Eklund 17B 
To determine the thermal death of spores of Group I strain Af84, spores were heated at 
95°C for 1, 2, 3, 4, 5 and 6 hours in Sorenson’s phosphate buffer, cooled and inoculated 
onto PYGS medium, incubated at 37°C for 2 days and then the number of colonies formed 
enumerated (Figure 5). Spores were heated for a total of 6 hours, however after 6 hours of 
heating, no colonies were observed on PYGS medium. The D95°C-value, which is the time 
required to reduce spore viability by a factor of ten at 95°C, for Group I strain Af84 was 69 
minutes (Figure 5). Thus, heating Group I strain Af84 for 4 hours at 95°C was sufficient to 
deliver a 3-log reduction in spore viability.  
 
 
 
Figure 5. Number of surviving spores of C. botulinum Group I strain Af84 plated on PYGS 
medium after heat inactivation at 95°C, at various time intervals. No spores were 
recovered after 6 hours of heating on PYGS medium.  
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Heat inactivation of C. botulinum Group II strain Eklund 17B was measured at 85°C (Figure 
6). Spores were heated for 1, 2, 5, 10 and 20 minutes in Sorenson’s phosphate buffer, 
cooled on ice, spread onto PYGS medium and incubated at 30°C for 2 days. After 2 minutes 
at 85°C, no colonies were observed on PYGS medium. The D85°C-value for C. botulinum 
Group II strain Eklund 17B was 0.19 minutes, which was calculated using the equation of 
the dashed line in figure 6.  Heating Eklund 17B spores for 1 minute at 85°C delivered a 5-
log reduction in spore viability.  
 
 
 
 
 
 
 
 
 
Figure 6. Number of surviving spores of C. botulinum Group II strain Eklund 17B plated 
on PYGS medium after heat inactivation at 85°C, at various time points. After 2 minutes 
of heating at 85°C (and longer), no spores were recovered on PYGS plates.  
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3.2 L-alanine and L-cysteine germinate spores of C. botulinum Group I and II 
Germination of Group I strain Af84 and Group II strain Eklund 17B with the nutrient 
germinants L-alanine and L-cysteine was evaluated by measuring the fall in OD600 over time 
using a Bioscreen C analyser. Germination of Af84 with L-cysteine occurred at a faster rate 
than with L-alanine, and L-cysteine germination was completed within 10 hours (Figure 7). 
For L-cysteine, a 65% drop in OD600 was observed representing ~99% spore germination of 
Group I strain Af84, as determined by phase-contrast microscopy. Germination of Group I 
Strain Af84 with L-alanine was complete within 18 hours and a fall in OD600 of ~50% 
resulted in ~99% phase dark spores. Group II strain Eklund 17B germinated with both L-
alanine and L-cysteine at a similar rate and germination was completed within the first 
hour of the experiment for both germinants. An 80% fall in OD600 with L-alanine resulted in 
~99% spores germinating. In comparison, a 75% fall in OD600 with L-cysteine resulted in 
~99% spores germinating, as determined by phase-contrast microscopy. There was no fall 
in OD600 in the absence of L-alanine or L-cysteine (controls in Figure 7). L-alanine and L-
cysteine were both efficient germinants for Eklund 17B, however L-cysteine germinated 
Af84 at a faster rate when compared to the germinant L-alanine.  
Figure 7. Anaerobic germination of C. botulinum Group I strain Af84 and Group II strain Eklund 
17B with the nutrient germinants, L-alanine (50mM) and L-cysteine (50mM) in Tris-HCl buffer 
(20mM, pH 7.4) at 30°C, using a Bioscreen C analyser system to measure OD600. 
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3.3 Exogenous CaDPA does not induce germination in C. botulinum Group I strain 
Af84 or Group II strain Eklund 17B at 30°C 
The effect of exogenous CaDPA on spore germination was examined by measuring the fall 
in OD600, using a Bioscreen C Analyser (Figure 8). Exogenous CaDPA did not induce 
germination in C. botulinum Group I strain Af84 or Group II strain Eklund 17B. However, 
small decreases in OD600, ~10% for Group I strain Af84 and 18% for Group II strain Eklund 
17B, were observed in the experiment. Microscopic analysis of spores incubated with 
CaDPA for 24 hours confirmed that no germination had occurred, with all spores remaining 
phase bright. 
 
 
 
 
Figure 8. Anaerobic germination of C. botulinum Group I strain Af84 and Group II strain 
Eklund 17B with the non-nutrient germinant CaDPA (54mM) at 30°C, using a Bioscreen C 
analyser system to measure OD600. 
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3.4 Exogenous CaDPA did not induce germination of coated or decoated spores of 
C. botulinum Group I strain Af84 or Group II strain Eklund 17B at 45°C 
The ability of the non-nutrient germinant CaDPA to germinate spores of Group I strain Af84 
and Group II strain Eklund 17B was further assessed at 45°C, as some previous work had 
indicated a greater effect of CaDPA on spore germination at 45°C (Riemann and Ordal, 
1961). Spores of Group I strain Af84 with intact coats and coats removed showed a 
decrease in OD600 of ~17% and 30%, respectively (Figure 9). However, the control spores 
(no CaDPA) with intact coats and control spores (no CaDPA) with absent coats also showed 
a drop in OD600 of approximately 25%. Visualisation of all samples under phase-contrast 
microscopy revealed no germination had occurred as all of the spores remained phase 
bright. Although initial results showed a drop in OD600 by approximately 17% for spores of 
Group II strain Eklund 17B with intact coats, microscopic analyses revealed that all of the 
spores appeared phase bright. Decoated spores of Eklund 17B also showed signs of 
germination, as the OD600 had fallen by ~13%. However, all the spores appeared phase 
bright when viewed under phase-contrast microscopy. Both controls showed a slight drop 
in OD600, 20% and 5% for coated and decoated controls, respectively, but remained phase 
bright (controls not shown).  
Figure 9. Anaerobic germination of C. botulinum Group I strain Af84 and Group II strain 
Eklund 17B with the non-nutrient germinant CaDPA (54mM) at 45°C, using a Bioscreen C 
analyser system to measure OD600. Spores were decoated using dithiothreitol. 
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3.5 Germination assay using microscopic analyses of spores of C. botulinum Group 
I strain Af84 and Group II strain Eklund 17B gave similar results to those using the 
Bioscreen  
Spores were examined for germination with L-alanine, L-cysteine and CaDPA by measuring 
(using a microscope) the percentage of phase-dark spores at varying time intervals at 30°C 
(Figure 10). Results were consistent with those obtained using the Bioscreen. 
Approximately 95% of spores of strain Af84 incubated with L-alanine appeared phase dark 
after 20 hours, with only ~5% spores remaining phase bright. In the presence of L-cysteine, 
approximately 90% of spores of strain Af84 appeared phase-dark after 20 hours of 
incubation. Germination of strain Eklund 17B with L-alanine proceeded more rapidly than 
strain Af84 with approximately ~50% of spores appearing phase bright after 10 minutes of 
incubation with the germinant. After 20 hours, >99% spores of Eklund 17B appeared phase 
dark under the microscope. Germination of strain Eklund 17B with L-cysteine appeared to 
proceed at a similar rate to L-alanine, as found by measuring the fall in OD600 using the 
Bioscreen (Figure 7). No phase dark spores were observed for controls (no germinant) or 
spores incubated with CaDPA for the entirety of the experiment (data not shown).  
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Figure 10. Percentage of phase dark spores observed over time using phase-contrast 
microscopy with C. botulinum Group I strain Af84 and Group II strain Eklund 17B. Spores were 
incubated with L-alanine (50mM) and L-cysteine (50mM) in Tris-HCl buffer (20mM, pH 7.4) at 
30°C. 
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3.6 DDA induced germination in spores of C. botulinum Group I strain Af84 and 
Group II strain Eklund 17B  
Germination of Group I strain Af84 and Group II strain Eklund 17B with 1.08mM DDA was 
measured at 45°C (Figure 11). Spores of both strains germinated in the presence of DDA, 
showing a fall in OD600 by 35% and 40% for Af84 and Eklund 17B, respectively. The control 
(no DDA addition) for strain Af84 showed a small drop in OD over the 24-hour period. The 
Eklund 17B control (no DDA addition) increased in OD600 by approximately 15% in the first 
hour of the study, however the OD600 subsequently returned to its original OD600 and 
remained relatively constant for the remainder of the study. Following 24 hours incubation 
with DDA, spores were examined under phase contrast microscopy. Spores of Group I 
strain Af84 had ~50% phase bright spores remaining. Spores of Group II strain Eklund 17B 
appeared ~40% phase bright under the microscope. All controls were observed under the 
microscope and >99% spores appeared phase bright. Finally, DDA germination was also 
analysed using decoated Eklund 17B spores (data not shown). Interestingly, removal of the 
spore coats prevented any spore germination with DDA. 
 
 
Figure 11. Anaerobic germination of C. botulinum Group I strain Af84 and Group II strain 
Eklund 17B with the non-nutrient germinant DDA (1.08mM) at 45°C, using a Bioscreen C 
analyser system to measure OD600.  
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3.7 Lysozyme does not have an inhibitory effect on growth from spores of C. 
botulinum Group I strain Af84 or Group II strain Eklund 17B  
The effect of lysozyme concentration on the growth of C. botulinum Group I and II strains 
was evaluated by inoculating unheated spores  (OD600 ~0.5) of each strain onto PYGS agar, 
supplemented with different concentrations of lysozyme (0, 1, 3, 10, 30 and 100µg/ml) at 
37°C and 30°C, respectively (Figure 12). There was no effect of lysozyme concentration on 
the viable count of Group II strain Eklund 17B. The viable count for Group I strain Af84 was 
also unaffected by the lysozyme concentration and was approximately 1-log lower than for 
Group II strain Eklund 17B, due to a lower initial spore concentration.  
 
 
 
 
Figure 12. The effect of lysozyme concentration (µg/ml) on anaerobic growth of Group I 
strain Af84 and Group II strain Eklund 17B at 37°C and 30°C, respectively. The standard 
deviation is shown. 
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3.8 Lysozyme induces germination of decoated spores of C. botulinum Group I 
strain Af84 and Group II strain Eklund 17B 
The ability of lysozyme (10µg/ml) to germinate spores of Group I strain Af84 was 
determined at 37°C (Figure 13). Spores of strain Af84 that had been previously decoated 
using sodium thioglycolate showed a slight decrease in OD600 of 25% within 9 hours (Figure 
13). Microscopic visualisation, after 24 hours, revealed very low spore titres, compared to 
that observed prior to the addition of lysozyme. However, a small number of clumps of 
~98% phase dark (germinated) spores were observed. A haemocytometer was used to 
enumerate, more accurately, the number of decoated spores of strain Af84 following 
germination in the presence of lysozyme. There was a 99% decrease in the total spore 
count after 24 hours incubation, suggesting that the spores had germinated and lysed. 
Coated spores of Af84 decreased in OD600 by ~25% within 24 hours, however, these spores 
all appeared phase bright under the microscope (and there was no decrease in spore titre). 
The controls used in this experiment were spores of Af84 incubated with Tris-HCl buffer 
without the addition of lysozyme. Both controls (coated and decoated) remained 100% 
phase-bright when observed using phase-contrast microscopy. The buffer only control 
(Tris-HCl only) which contained no spores remained at a constant OD600 for the entirety of 
the experiment.  
Figure 13. Anaerobic germination of C. botulinum Group I strain Af84 with lysozyme 
(10µg/ml) at 37°C using a Bioscreen C analyser to measure OD600. Spores were decoated 
using sodium thioglycolate.  
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Lysozyme (10µg/ml) was also tested as a germinant for Group II strain Eklund 17B (Figure 
14). Germination of decoated spores of Eklund 17B was complete within 2 hours of 
incubation with lysozyme, which corresponds with a 55% fall in OD600 resulting in ~99% 
spores appearing phase dark under phase-contrast microscopy. Even though an ~18% fall in 
OD600 was observed for coated spores of Eklund 17B that had been incubated with 
lysozyme, approximately 99% of these spores appeared phase bright when visualised under 
phase-contrast microscopy. Decoated total spore titres remained the same for Group II 
strain Eklund 17B after incubation in lysozyme. None of the controls germinated, as all 
spores appeared phase-bright. The buffer only control, which contained no spores, 
remained at a constant OD600 throughout the experiment.  
Germination of both strains with lysozyme was also tested using dithiothreitol as the 
decoating reagent rather than sodium thioglycolate, and similar results were obtained with 
both decoating reagents. 
 
 
 
 
 
Figure 14. Anaerobic germination of C. botulinum Group II strain Eklund 17B with lysozyme 
(10µg/ml) at 37°C using a Bioscreen C analyser to measure OD600. Spores were decoated 
using sodium thioglycolate.  
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3.9 Lysozyme recovers heat-damaged spores of C. botulinum Group II strain 
Eklund 17B but not spores of Group I strain Af84 
The ability of lysozyme (10µg/ml) to recover spores of Group I strain Af84 and Group II 
strain Eklund 17B was evaluated (Figure 15). Spores of Group I strain Af84 and Group II 
strain Eklund 17B were heat inactivated by submerged heating for 4 hours at 95°C and 2 
minutes at 85°C, respectively. After heating, no spores of Group I strain Af84 were 
recovered on either PYGS alone or PYGS with lysozyme, regardless of whether the spore 
coat had been removed or remained intact. Viable counts for unheated Af84 spores 
(coated and decoated) were similar on PYGS medium and PYGS with lysozyme. There was a 
1-log difference in the viable count between unheated coated spores and unheated 
decoated spores on both PYGS medium and PYGS supplemented with lysozyme (Figure 15). 
Following heat treatment, coated spores of Group II strain Eklund 17B were not recovered 
on unsupplemented PYGS medium. In comparison, when heat treated spores were plated 
on PYGS medium supplemented with lysozyme (10µg/ml), a >4.4-log increase in recovery 
was observed. When spores of Eklund 17B had their coats chemically removed using 
sodium thioglycolate, there was a ~2-log increase in recovery compared to coated spores 
when spread onto PYGS medium supplemented with lysozyme. For heat-treated decoated 
spores of Group II strain Eklund 17B, there was a total increase in recovery of >5.9-log 
when plated onto PYGS medium containing lysozyme, compared to heat treated spores 
spread onto unsupplemented medium. Unheated spores of Eklund 17B with an intact coat 
formed colonies on both types of media, although when the spore coat was removed the 
recovery rate was reduced (Figure 15).  
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Figure 15. Number of surviving spores (±SD) after heat inactivation (Eklund 17B, 85°C for 2 
minutes; Af84, 95°C for 4 hours) and recovery on PYGS agar supplemented with lysozyme 
(10µg/ml). Spores were decoated using sodium thioglycolate.  
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3.10 Spores of C. botulinum Group I strain Af84 and Group II strain Eklund 17B 
cannot be recovered with DDA after heat inactivation  
It was previously shown (Figure 11) that unheated spores of strains Af84 and Eklund 17B 
with an intact coat are able to germinate in response to DDA (1.08mM). The recovery of 
heat-damaged spores with DDA was now tested (Figure 16). Spores were heated in a water 
bath at 95°C for 4-hours and at 85°C for 2 minutes for Group I strain Af84 and Group II 
strain Eklund 17B, respectively. A proportion of spores were pre-incubated with DDA 
(1.08mM) overnight (coated and decoated) and rinsed to minimise DDA toxicity. The 
subsequent formation of colonies from spores of Group I strain Af84 and Group II strain 
Eklund was now measured. Unheated spores of Group I strain Af84 formed colonies on 
PYGS agar with and without prior incubation with DDA. However, the viable count was 
marginally lower with DDA incubation than without for coated and decoated spores of 
Group I strain Af84 (Figure 16). After heat inactivation at 95°C for 4 hours, colonies of strain 
Af84 were not formed when incubated with DDA (coated nor decoated). There were also 
no colonies formed from heated spores of strain Af84 when spread onto PYGS without 
prior DDA incubation.  
Unheated spores of strain Eklund 17B (coated and decoated) formed colonies on PYGS 
medium, both with and without prior DDA incubation. Decoating of the spores and 
incubation with DDA each brought about a reduction in the viable count from unheated 
spores (Figure 16). After heat inactivation of spores of Eklund 17B at 85°C for 2 minutes, no 
spores (coated nor decoated) were recovered on PYGS medium with or without prior DDA 
incubation.  
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Figure 16. Number of surviving spores (±SD) after heat inactivation (Eklund 17B, 85°C for 2 
minutes; Af84, 95°C for 4 hours) and recovery on PYGS agar after incubation with DDA 
(1.08mM) overnight at 45°C. Spores were decoated using sodium thioglycolate.  
0
1
2
3
4
5
6
7
PYGSPYGS
+
DDA
PYGSPYGS
+
DDA
PYGSPYGS
+
DDA
PYGSPYGS
+
DDA
PYGSPYGS
+
DDA
PYGSPYGS
+
DDA
PYGSPYGS
+
DDA
PYGSPYGS
+
DDA
Coated Decoated Coated Decoated Coated Decoated Coated Decoated
Unheated Heated Unheated Heated
Eklund 17B Af84
Lo
g 
N
u
m
b
er
 o
f 
Su
rv
iv
o
rs
 (
C
FU
/m
l)
47 
 
3.11 Spores of C. botulinum Group I strain Af84 and Group II strain Eklund 17B 
cannot be recovered with L-alanine after heat-inactivation 
Spores of Group I strain Af84 and Group II strain Eklund 17B were previously shown to 
germinate in response to the nutrient germinant L-alanine (50mM) (Figure 7). The use of L-
alanine to recover heat-damaged spores when inoculated onto PYGS agar supplemented 
with L-alanine (50mM) was evaluated (Figure 17). Unheated spores of Group I strain Af84 
formed colonies on PYGS medium and PYGS supplemented with L-alanine and the viable 
count was similar for each media for coated and decoated spores. There was an 
approximately 1-log difference between the viable counts for coated and decoated spores. 
No colonies were formed from spores of Group I strain Af84 that had been heated for 4 
hours at 95°C, even on the PYGS plates that had been supplemented with L-alanine. 
Unheated and coated spores of Eklund 17B gave similar viable counts on PYGS and PYGS 
supplemented with L-alanine. The number of colonies formed from unheated and decoated 
spores was similar on the two media, but lower than that for coated spores (Figure 17). 
Following a heat treatment at 85°C for 2 minutes, no colonies were formed on PYGS or 
PYGS with L-alanine supplementation.  
Figure 17. Number of surviving spores (±SD) after heat inactivation (Eklund 17B, 85°C for 2 
minutes; Af84, 95°C for 4 hours) and recovery on PYGS agar with L-alanine (50mM). Spores 
were decoated using sodium thioglycolate.  
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3.12 Timing of DPA release during germination of C. botulinum Group I strain Af84 
and Group II strain Eklund 17B with L-alanine  
Various concentrations of DPA were incubated with TbCl3 (800µM), to determine the 
relationship between relative fluorescence and DPA concentration (Figure 18). The highest 
concentration of DPA used, corresponded to a fluorescence reading of ~240000AU. The 
minimum concentration of DPA that was detectable during this assay was 1µM, which 
corresponded to ~145000 fluorescence AU. The assay was not very sensitive for the lower 
concentrations of DPA (0-10µM), as represented by an R2 of 0.293.  
 
Figure 18. Effect of DPA concentration on the relative fluorescence (550nm) following 
binding to TbCl3. Insert (a) represents fluorescence readings for low concentrations of DPA 
(0-10µM). 
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In order to determine the timing of DPA release in spores of Group I strain Af84, spores 
were incubated with L-alanine (50mM) and TbCl3 (800µM) and monitored over 18 hours at 
25°C using a fluorescence plate reader (Figure 19). The fluorescence increased steadily 
from ~120000AU to ~160000AU over the 18 hour period, while the OD600 decreased quickly 
and then slowly and then quickly again (Figure 19). Overall, the OD600 fell to 55% of the 
initial value. Associating results from Figure 19 to the calibration curve in Figure 18, it 
shows that a total fluorescence reading of 160000AU corresponds to a final DPA 
concentration of 15µM. This is 0.005pg of DPA released per spore of strain Af84 during 
germination with L-alanine. In the absence of L-alanine, there was no fall in OD600 detected 
and only a marginal increase in fluorescence, which does not signify DPA release (Figure 
20). 
Figure 19. Timing of DPA release in spores of C. botulinum Group I strain Af84 compared to 
the change in OD600 observed following the addition of the germinant L-alanine (50mM). 
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Figure 20. Lack of DPA release and change in OD600 for spores of Group I strain Af84 
without the addition of L-alanine (50mM). 
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Spore germination of Group II strain Eklund 17B in the presence of L-alanine (as measured 
by change in OD600) and DPA release were both more rapid than observed with Group I 
strain Af84 (Figure 19). A total fluorescence reading of ~150000AU was detected within 50 
minutes of incubation with the nutrient germinant L-alanine and the fluorescence reading 
remained relatively constant for the remainder of the incubation period. A fluorescence 
reading of ~150000AU correlates with a final DPA concentration of ~8µM (Figure 18) 
released from spores of Group II strain Eklund 17B, when germination is induced by L-
alanine. The amount of DPA released per spore of strain Eklund 17B during germination 
with L-alanine is 0.003pg. In the absence of L-alanine, there was no increase in fluorescence 
or fall in OD600 (Figure 22). 
 
 
 
 
 
Figure 21. Timing of DPA release in spores of C. botulinum Group II strain Eklund 17B 
compared to the change in OD600 observed following the addition of the germinant L-
alanine (50mM). 
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Figure 22. Lack of DPA release and change in OD600 for spores of Group II strain Eklund 17B 
without the addition of L-alanine (50mM). 
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3.13 The average DPA content per spore of C. botulinum Group II strain Eklund 
17B is higher than Group I strain Af84 
A known concentration dilution series of spores of Group I strain Af84 was autoclaved at 
121°C for 15 minutes. The most concentrated sample contained 107 spores/ml, measured 
using a haemocytometer. Diluted samples (105-101) gave fluorescence readings lower than 
that detectable on the calibration curve (Figure 23). A calibration curve was produced for 
each C. botulinum strain to ensure plate to plate variation did not interfere with results 
obtained during the assay. The most concentrated sample for strain Af84 (8.7x107 
spores/ml) gave a fluorescence reading of 191706AU (Figure 24), which corresponds to a 
DPA concentration of 50μM using the calibration curve in Figure 24 and the estimated 
resulting average DPA concentration of Group I strain Af84 is 1.9pg/spore.  
 
 
 
 
 
 
 
 
 
 
Figure 23. Calibration curve for autoclaved spores of C. botulinum Group I strain Af84. 
Insert (a) represents fluorescence readings for lowest concentrations of DPA used (0-
10µM). 
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Figure 24. Fluorescence reading of DPA released from autoclaved spores of C. botulinum 
Group I strain Af84 at different dilutions.  
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Spores of Group II strain Eklund 17B were also enumerated and serially diluted, prior to 
autoclaving at 121°C for 15 minutes. DPA in the supernatant of autoclaved spores was 
detected using TbCl3 and fluorescence was measured using a plate reader. There was a 
linear relationship between spore concentration and fluorescence (Figure 25). The DPA in 
the supernatant of spores in the lowest dilutions (106-101) was not readily quantifiable 
(fluorescent readings ranged from 130000-138000AU) (Figure 26). As mentioned above, a 
separate calibration curve was produced for each strain to reduce plate to plate variability. 
The highest concentration (1x108 spores/ml) of Eklund 17B spores yielded a fluorescence 
reading of ~210000AU, which corresponds to 64μM DPA using the calibration curve in 
Figure 25 and the resulting estimated DPA concentration is 2.1pg/spore.  
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Calibration curve for autoclaved spores of C. botulinum Group II strain Eklund 
17B. Insert (a) represents fluorescence readings for DPA concentrations 0-10µM. 
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Figure 26. Fluorescence reading of DPA released from autoclaved spores of C. botulinum Group II 
strain Eklund 17B at different dilutions.  
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3.14 Summary of Results 
 
 Heating C. botulinum Group II strain Eklund 17B for 1 minute at 85°C is enough to 
deliver a 5-log reduction in spore viability  
 Heating C. botulinum Group I strain Af84 for 4 hours at 95°C is sufficient to deliver a 
3-log reduction in spore viability 
 Nutrient germination of C. botulinum Group I strain Af84 and Group II strain Eklund 
17B occurs with both L-alanine and L-cysteine, at varying efficacy 
 Spores of C. botulinum Group I strain Af84 and Group II strain Eklund 17B do not 
germinate in response to the addition of exogenous CaDPA 
 Spores of C. botulinum Group I strain Af84 and Group II strain Eklund 17B with an 
intact coat germinate in response to DDA (but not spores with the coat removed) 
 Decoated spores of C. botulinum Group I strain Af84 and Group II strain Eklund 17B 
both germinate with the addition of lysozyme  
 Spores of C. botulinum Group II strain Eklund 17B were recovered with lysozyme 
(10µg/ml) after heating for 2 minutes at 85°C 
 Decoated spores of Eklund 17B gave the highest spore recovery yield compared to 
coated spores when incubated with PYGS medium containing lysozyme (10µg/ml) 
 Spores of C. botulinum Group I strain Af84 were not recovered with lysozyme 
(10µg/ml) after heating for 4 hours at 95°C 
 Heated spores of C. botulinum Group I strain Af84 and Group II strain Eklund 17B 
were not recovered with DDA or the nutrient germinant L-alanine 
 During germination, DPA is released within 18 hours for Group I strain Af84 and 
within 50 minutes for Group II strain Eklund 17B 
 The average DPA concentration per spore (following autoclaving) of Group I strain 
Af84 and Group II strain Eklund 17B is 1.9pg and 2.1pg, respectively.  
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4. Discussion 
4.1 Spore thermal death 
Spores of C. botulinum Groups I and II germinate under favourable conditions and produce 
vegetative cells that form the botulinum neurotoxin (Peck, 2009). The aim of this study was 
to confirm the germination pathways of C. botulinum Group I and Group II outlined by 
Brunt et al. (2016) and to determine which part of the germination apparatus is affected by 
heat, preventing germination, and thereby subsequent outgrowth and toxin formation. 
Food manufacturers employ rigorous processes in order to prevent foodborne botulism, 
including for the safe production of chilled ready-to-eat meals and canned goods (Peck, 
2006). The methods used to ensure the safety of food products include thermal processing 
and high-pressure treatment; there is also an increasing demand from consumers for 
minimally processed food (Bello et al., 2014). Many studies state that these two treatment 
methods act synergistically to ensure spore death because high-pressure treatment alone is 
insufficient to inactivate spores (Ananta et al., 2001, Okazaki et al., 2000, San Martín et al., 
2002).  
In the current work, thermal death experiments with Group I strain Af84, concluded that a 
4-hour heating time at 95°C was enough to deliver a 3-log reduction in spore viability. The 
D95°C-value was 69 minutes, and similar to that reported in the literature. There are limited 
recent publications establishing thermal death in Group I strains, however by extrapolation 
of results from Anderson et al. (1996) the D95°C-value for spores of Group I strain 213B is 
approximately 80 minutes. Similarly, an extensive study by Esty and Meyer (1922) 
determined the heating time required to prevent growth from ~6x1010 spores of Group I 
spores as being 4 minutes at 120°C, 10 minutes at 115°C, 32 minutes at 110°C, 100 minutes 
at 105°C and 330 minutes at 100°C. From this work, the D95°C-value can be estimated as 80 
minutes. Spores of C. botulinum Group I pose a threat to low-acid canned food and have a 
D121°C-value of 0.21 minutes, making them the most heat resistant group of C. botulinum 
(Peck, 2009). Spores of C. botulinum Group II are less heat-resistant than Group I, and in 
the present study, a 5-log reduction for spores of Group II strain Eklund 17B was achieved 
by heating at 85°C for 2 minutes, and the D85°C-value was 0.19 minutes. A previous study by 
Peck et al. (1992a), demonstrated that heating Group II strain Eklund 17B for one minute at 
85°C resulted in an approximate 5.5 log reduction in viable count. A review by Wachnicka 
et al. (2016) reported a similar spore resistance for other strains of C. botulinum Group II. 
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4.2 Spore germination in response to nutrient germinants 
Various amino acids are capable of germinating spores of Bacillus or Clostridium species by 
binding to specific protein complexes termed germinant receptors (Setlow, 2014). Spores 
of C. botulinum Group I and II germinate in response to a combination of nutrient and non-
nutrient germinants, particularly low-molecular weight biological molecules such as amino 
acids (Bhattacharjee et al., 2016, Peck, 2009). In the current study, tests were carried out to 
determine whether spores of Group I strain Af84 and Group II strain Eklund 17B respond to 
amino acid germinants. Heat activated spores were incubated with L-alanine and L-cysteine 
and their resulting change in optical density at 600nm was measured using a Bioscreen. 
Optical density decreases during germination due to the loss of CaDPA from the spore core 
and the uptake of water, which causes a change in the refractive index of the spore (Ghosh 
and Setlow, 2009). In the present study, germination occurred with Group I strain Af84 and 
Group II strain Eklund 17B in the presence of L-alanine or L-cysteine, with L-lactate and 
NaHCO3 in Tris-HCl buffer. The most effective amino acid germinant for Group I strain Af84 
in the present study was L-cysteine (with L-lactate and NaHCO3), and the most effective 
germinant for Group II strain Eklund 17B was L-alanine (with L-lactate and NaHCO3), albeit, 
the difference between L-alanine and L-cysteine germination for Group II strain Eklund 17B 
was minimal. A 50% drop in OD600 was observed for spores of Group I strain Af84 with L-
alanine/L-lactate/NaHCO3, whereas in a previous study, only a 30% fall in OD580 was 
observed for Group I strain Beans (NCTC 7273) in response to this germinant (Broussolle et 
al., 2002). These authors also reported that spores of Group I strain Beans do not decrease 
in OD580 with L-alanine as much as spores of the closely related organism C. sporogenes 
strain NCIMB 701792 (Broussolle et al., 2002). The difference in change in optical density 
observed for Group I strains in the current study compared to the study by Broussolle et al. 
(2002), could be due to the different strain of Group I used or the different method used to 
produce the spores. Similarly, in the study by Brunt et al. (2014), L-cysteine in combination 
with L-lactate/NaHCO3 also initiated germination most effectively in strains of Group I and 
C. sporogenes, even though L-alanine had a lower minimum effective germination 
concentration than L-cysteine. Germination of Group I strain ATCC 3502 was most effective 
with L-phenylalanine rather than L-alanine, which may suggest that amino acid germinants 
are species and strain specific (Brunt et al., 2014). Brunt et al. (2014) also stated that L-
lactate was not an essential requirement for germination of Group I strain ATCC 3502 with 
L-alanine or L-cysteine. Interestingly, a paper by  Meaney et al. (2015) suggested that 
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NaHCO3 is required for spore germination in C. botulinum Group I strain ATCC 3502 rather 
than L-lactate.  
The effect of numerous amino acids on the germination of spores of C. botulinum Group II 
strains Eklund 17B, Beluga and Craig 610 was studied by Plowman and Peck (2002). The 
amino acids L-alanine, L-serine and L-cysteine were the most effective germinants for 
spores of Group II strains, in combination with L-lactate/NaHCO3 in phosphate buffer. The 
results obtained by Plowman and Peck (2002), revealed that L-cysteine supplemented with 
both L-lactate/NaHCO3 produced the most rapid germination in the strains of C. botulinum 
Group II. However none of the amino acids germinated spores in the absence of L-lactate.  
One hypothesis for the difference in which amino acid was the most effective between L-
alanine and L-cysteine for spores of strain Eklund 17B in the present study and a previous 
study by Plowman and Peck (2002), may be due to the different sporulation conditions 
used. Recent publications have shown that the sporulation condition has a direct effect on 
the germinating capability of the spore (Brunt et al., 2014, Meaney et al., 2015). A positive 
correlation has been reported between spore yield and germination rate in C. sporogenes, 
a surrogate for C. botulinum Group I, whereas for C. botulinum Group II spore yield was 
affected by sporulation temperature, but not the germination or heat resistance properties 
of the spore (Brunt et al., 2014, Peck et al., 1995). In a study by Hornstra et al. (2006), the 
rate and efficiency of germination of spores of B. cereus were greatly decreased when 
spores were produced in suboptimal conditions, mimicking the sporulation environment 
that contaminating spores of B. cereus are formed in, as often the food environment is less 
than optimal in terms of temperature and composition of media (Hornstra et al., 2006). 
Thus, challenge tests in foods may be more realistic if the spores used have been formed in 
conditions relevant to product contamination, and it may also provide a more realistic 
model for characterising spore germination (Ramirez-Peralta et al., 2012).  
Spores of Group I strain Af84 and Group II strain Eklund 17B respond most effectively with 
different amino acid stimuli (L-cysteine for Group I strain Af84 and L-alanine for Group II 
strain Eklund 17B), which may be due to the different germination pathways in the two 
groups of C. botulinum. The germinant receptors differ between C. botulinum Group I and 
Group II strains; there are three germinant receptors in Group I strains (GerX1, 2, 3) with 
one (GerX1) dominant, whereas there is only one class of germinant receptor in Group II 
strains, which is similar in orientation to GerX3 in Group I, and for simplicity is also termed 
GerX3 (Brunt et al., 2014). Amino acids bind to inner membrane germinant receptors and 
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the differences in the number and types of germinant receptors in Group I and Group II 
may explain the varied germination that occurred with the amino acids tested in both 
strains during this study.  
 
4.3 Spore germination in response to CaDPA 
Non-nutrient germinants are able to germinate spores of Bacillus and Clostridium by 
bypassing the germinant receptors located in the inner membrane (Paidhungat and Setlow, 
2000). The most studied non-nutrient germinants in Bacillus species include CaDPA and 
DDA, however these are only relevant in laboratory studies (Setlow, 2013).  The mechanism 
by which exogenous CaDPA is able to germinate spores of B. subtilis was proposed by 
Paidhungat and Setlow (2000) and suggested that CaDPA may activate a downstream 
effector in B. subtilis because it does not require the GerA receptor family in order to 
germinate. More recently, CaDPA has been shown to activate the cortex lytic enzyme CwlJ 
in B. subtilis, without involving a germinant receptor (Setlow, 2013). Unlike germinant 
receptors, CwlJ is located within the cortex-coat boundary rather than in the inner 
membrane (Bagyan and Setlow, 2002). In the current study, exogenous CaDPA did not 
stimulate germination in Group I strain Af84 or Group II strain Eklund 17B. The reasons for 
this are not clear, however, germination with CaDPA may be species or strain dependent.  
In the literature, no data are available for exogenous CaDPA-induced germination of spores 
of C. botulinum; however, there have been previous studies, which show that some 
Clostridia, such as C. perfringens, are able to germinate effectively with CaDPA, such as the 
recent studies by Paredes-Sabja et al. (2009b) and Wang et al. (2012). These studies 
showed that C. perfringens, a foodborne pathogen capable of causing gastrointestinal 
disease in humans and animals and the causative agent of gas gangrene, is able to 
germinate in response to CaDPA (Myers et al., 2006, Paredes-Sabja et al., 2009b, Wang et 
al., 2012). Notably, CaDPA seems to initiate germination in C. perfringens by activating the 
GerK germinant receptor, rather than by activating the CwlJ cortex lytic enzyme, which is 
the mechanism by which CaDPA induces germination in B. subtilis and B. megaterium 
(Paredes-Sabja et al., 2008, Setlow et al., 2009). Germinant receptors in similar 
configuration to GerK are present in C. botulinum Group I and II (Brunt et al., 2016).  
Spores of C. difficile, the leading cause of gastroenteritis and infectious nosocomial 
diarrhoea in the UK and US, did not germinate with exogenous CaDPA (Wang et al., 2015). 
One hypothesis was that this was due to the lack of inner membrane germinant receptors 
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in C. difficile (Lessa et al., 2015, Wang et al., 2015). A later study by Kochan et al. (2017) 
showed that exogenous CaDPA is unable to germinate spores of  C. difficile, unless 
supplemented with taurocholate. In the same study, it was also found that CaCl2 with 
taurocholate induced germination of C. difficile in the absence of exogenous DPA. 
Contrastingly, B. anthracis was able to germinate in response to CaDPA but germination 
with CaCl2 alone was unsuccessful. As a result,  it has been hypothesised in the literature 
that calcium ions can function as co-germinants and initiate cortex hydrolysis by activating 
SleC, rather than CwlJ, in C. difficile (Kochan et al., 2017).  
Interestingly, spores of C. sporogenes, a surrogate for C. botulinum Group I, are capable of 
germinating with exogenous CaDPA (Brunt, personal communication). This may suggest 
that the germination mechanism in these species is subtly different and raises the question 
as to whether C. sporogenes should be used as a surrogate in germination studies, even 
though they are genetically closely related. A similar comment was made by Brunt et al. 
(2014) based on the characterisation of nutrient germinant receptors. The conditions in 
which spores are prepared could have had an effect on the ability of spores to germinate 
with CaDPA. However, this possibility is not supported by the recent findings by Ramirez-
Peralta et al. (2012) who reported that germination rates in B. subtilis with exogenous 
CaDPA were relatively similar for spores produced in a poor-medium at 23°C compared to 
spores prepared in a rich-medium at 37°C. As mentioned earlier, CaDPA activates CwlJ in B. 
subtilis, SleC in C. difficile and GerK in C. perfringens, which suggests that something is 
preventing exogenous CaDPA-induced germination in C. botulinum Group I strain Af84 and 
Group II strain Eklund 17B as CwlJ is present in the germination mechanism of C. botulinum 
Group I, SleC is involved in the germination mechanism of C. botulinum Group II and both C. 
botulinum Groups I and II contain a germinant receptor in a similar arrangement to GerK.  
 
4.4 Spore germination in response to DDA 
Dodecylamine (DDA) was first reported as a non-nutrient germinant for spores of B. 
megaterium in 1960 (Rode and Foster, 1960). Since then, further investigation into cationic 
surfactant-induced germination has been conducted with spores of B. subtilis, using genetic 
mutations to determine the germination mechanism utilised, in particular by the primary 
alkylamine DDA (Christie, 2012). One study in particular has shown that germination of 
spores of B. subtilis with DDA follows a similar mechanism to high-pressure stimulated 
germination, where the germinant receptors are bypassed at low concentrations, and DPA 
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release and cortex lytic enzyme activation occurs via another mechanism (Setlow et al., 
2003). Understanding the mechanism by which DDA induces germination could be 
beneficial to food industry because DDA germinated spores are less heat resistant and 
more prone to environmental stresses than dormant spores. Thus, inducing germination by 
using cationic surfactants in food products could reduce the requirement for thermal 
processing at high temperatures, improve taste, reduce energy consumption and reduce 
cost for the producer (Setlow, 2000, Setlow et al., 2003). Results obtained during the 
current study show that DDA-induced germination occurs with Group I strain Af84 and 
Group II strain Eklund 17B, however prior removal of the spore coat prevented 
germination.  In the study by Setlow et al. (2003), the effect of DDA on spores of B. subtilis 
was measured by monitoring DPA release using OD270. This study suggested that spore 
clumping caused by the addition of DDA can affect OD600 readings and therefore, a 
decrease in OD600 may not necessarily correlate with phase dark spores, hence why OD270 
was used instead. Results from Setlow et al. (2003) showed that not only did DDA 
germinate spores of B. subtilis, it also killed germinated spores; a phenomena previously 
described by Rode and Foster (1961).  
In the study by Setlow et al. (2003), DDA induced germination of B. subtilis spores at 37°C. 
Similarly, germination of C. botulinum in the current study occurred with DDA. Germination 
in B. subtilis occurred in spores with defective germinant receptors and spores missing the 
cortex lytic enzymes CwlJ or SleB (Setlow et al., 2003). Decoating spores of C. botulinum 
prior to incubation with DDA was carried out during the present study and it was evident 
that decoating spores prevented spore germination as the spores remained entirely phase-
bright. This may suggest that germination with DDA requires an unknown protein, which is 
located in the spore coat, and hence, when the coat is removed germination with DDA 
ceases. In contrast, decoating spores of B. subtilis had little effect on germination with DDA 
(Setlow et al., 2003). A study by Vepachedu and Setlow (2007) also observed B. subtilis 
germination with DDA and found that the rate of germination with DDA increased as SpoVA 
levels increased. Thus, DDA may induce germination in spores of B. subtilis via channels 
composed of SpoVA proteins (Vepachedu and Setlow, 2007). In the present study, DDA 
addition brought about a 35% reduction in OD600 over a 24 hour period for spores of Group 
I strain Af84 and ~50% spores appeared phase dark using phase-contrast microscopy. 
Spores of Group II strain Eklund 17B germinated more efficiently in response to DDA, with a 
40% fall in OD600 observed, and ~60% phase dark spores. During end-point microscopic 
analysis, not all of the spores appeared phase dark, which is a similar finding to results 
64 
 
published by Setlow et al. (2003), where they reported that only 75% of B. subtilis became 
phase dark in response to DDA. Interestingly, Setlow et al. (2003) also found that spores 
prepared in solid medium did not germinate as effectively with DDA as spores prepared in 
liquid medium. The spores used in the present study were prepared on a solid medium, 
and although a high yield of spores was produced, this may partly explain why spores did 
not germinate fully with DDA. Previous publications on B. megaterium have suggested that 
spores germinated with cationic surfactants, such as DDA, lose some of their refractiveness 
under phase-contrast microscopy and germinated spores may not appear as phase dark as 
they would if they had undergone nutrient germination (Rode and Foster, 1960, Rode and 
Foster, 1961). Therefore, difficulties in estimating the number of phase bright and phase 
dark spores during the current study may also be an issue. Germination in C. perfringens 
occurred with DDA, interestingly, it was also noted that germinated spores of C. perfringens 
were not as phase-dark in appearance as expected when compared to nutrient germinated 
spores (Paredes-Sabja et al., 2008). 
 
4.5 Spore germination in response to lysozyme 
Lysozyme was able to germinate spores of C. botulinum Group I strain Af84 and Group II 
strain Eklund 17B, once the spore coat had been removed. Previous studies have also 
shown lysozyme to have an effect on germination of spores of a wide variety of species, 
including B. subtilis and B. megaterium by activating part of the germination mechanism, 
independent of the germinant receptors or cortex lytic enzymes (Paidhungat and Setlow, 
2002, Suzuki and Rode, 1969). In C. botulinum, lysozyme has commonly been used to 
remove vegetative cells from spore crops by digestion (Grecz et al., 1962). A chemical 
treatment can be given to spores which disrupts the disulphide bonds in the spore coat 
resulting in complete removal of this layer and as a result spores are permeable to 
lysozyme and other lytic enzymes (Gould and Hitchins, 1963, Gould and Hitchins, 1965). 
After spore coat removal, lysozyme-induced germination can proceed as the enzyme can 
access the cortical mucopeptide substrate located below the spore coat (Gould and 
Hitchins, 1963). However, one study has shown that spores of B. megaterium do not 
require prior treatment to permeabilise the spore coat for germination with lysozyme to 
occur, suggesting that the lysozyme substrate is accessible to lysozyme without the need 
for spore coat degradation (Suzuki and Rode, 1969).  In the present study, germination of 
spores of C. botulinum Group I and Group II did not occur (as determined by change in 
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OD600) in spores that had an intact spore coat, which suggests that the spore coat structure 
is not permeable to lysozyme. In the current work, following removal of the spore coat, 
germination of Group I strain Af84 and Group II strain Eklund 17B occurred with a lysozyme 
concentration of 10µg/ml and resulted in a fall in OD600 of ~25% and ~55% for Group I strain 
Af84 and Group II strain Eklund 17B, respectively. In another study, the minimum 
concentration of lysozyme that initiated germination in spores of B. megaterium was 
1.5µg/ml, which resulted in an OD600 drop by 88% in the first 30 minutes (Suzuki and Rode, 
1969).  
 Determining the percentage of phase-dark spores after lysozyme incubation with Group I 
strain Af84 was challenging due to the apparent loss of spores during the germination tests. 
Counts using a haemocytometer revealed a reduction in the total spore titre when 
incubated with lysozyme, with no spores detected after 24 hours. Whereas, for Group II 
strain Eklund 17B, 24-hour incubation with lysozyme had little effect on the total spore 
titre. Osmotic rupture of Group I strain Af84 with lysozyme but not of Group II strain Eklund 
17B, suggests that there may be a difference in cortex structure between C. botulinum 
Group I and Group II. The presence of significant quantities of debris following the bursting 
of spores of Group I strain Af84 may explain why only a ~25% change in OD600 was observed 
during lysozyme germination, compared to a ~55% fall in OD600 for Group II. In the current 
study, varying concentrations of lysozyme (0, 1, 3, 10, 30, 100µg/ml) were tested to 
determine whether the enzyme had a toxic effect on cell growth from spores. The results 
showed no evidence of toxicity with similar viable counts at all of the tested concentrations 
of lysozyme. The concentration of lysozyme used in the present study was 10µg/ml, as this 
was the concentration previously shown to initiate germination in C. botulinum Group II 
strains (Lund and Peck, 1994).  
 
4.6 Determination of which part of spore germination apparatus is damaged by 
heat 
After determining the specific germinants and conditions that induce germination of 
unheated spores of Group I Strain Af84 and Group II strain Eklund 17B, the recovery of heat 
inactivated spores using these germinants was tested in order to begin to define which 
parts of the germination apparatus were damaged by heat. Studies in the literature have 
reported on the heat resistance of spores of C. botulinum in a variety of food products, 
however many of these studies fail to consider the effect of lysozyme, which when present 
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may increase spore survival (Lund and Notermans, 1992, Lund and Peck, 1994). During the 
current study, spores of Group I strain Af84 were not recovered on PYGS medium 
containing lysozyme (10µg/ml), regardless of whether the spore coat was made permeable 
by decoating. In contrast, plating heat-inactivated spores of Group II strain Eklund 17B with 
an intact spore coat on PYGS medium containing lysozyme (10µg/ml) increased spore 
recovery by >4.4-log. Furthermore, the recovery of heat-inactivated spores was increased 
to >5.8-log, when the spore coat was removed.  In a similar study by Peck et al. (1992a), the 
number of colonies formed on media containing lysozyme (10µg/ml) increased by a factor 
of 103-106, compared to the number of colonies formed on media without lysozyme for six 
different C. botulinum Group II strains after heat inactivation at 85°C for 10 minutes. For 
Group II strain Eklund 17B, a 5.5-log increase in survival of spores was observed when heat-
inactivated spores were plated on medium containing lysozyme (10µg/ml) and spores were 
still viable after 5 minutes of heating (Peck et al., 1992a).  Survival of decoated spores with 
lysozyme was also noted in a previous study by  Peck et al. (1992b), where the recovery of 
spores treated with thioglycolate was increased by approximately 3-log after prior heat 
treatment for 120 minutes at 85°C. The ability of lysozyme to recover a fraction of spores 
prior to chemical decoating in the present study suggests that the spore coat of Group II 
strain Eklund 17B is a permeable structure, with a small proportion of spores permeable to 
lysozyme. This small fraction could not be detected in the current study during germination 
assays of the spore population using the Bioscreen. The ability of lysozyme to recover 
spores of Group II strain Eklund 17B after heat inactivation at 85°C for 2 minutes, suggests 
that DNA within the spore is not damaged by this heat treatment. The inability of lysozyme 
to recover spores of Group I strain Af84 is not due to lysozyme preventing cell 
multiplication, nor to an inability of lysozyme to degrade the spore cortex, but may be due 
to the lytic effect that lysozyme has on spores during germination. Furthermore,  a previous 
report by Setlow (2014), stated that spores that had been germinated by lysozyme are 
prone to osmotic rupture due degradation of the germ cell wall by the muramidase. 
Another possible explanation of the inability of lysozyme to recover spores of Group I strain 
Af84 is that the spores are no longer viable (for example due to DNA damage).  
A study by Alderton et al. (1974) found that the addition of lysozyme to the recovery 
medium of heat-inactivated spores increased the recovery of a C. botulinum Group II type E 
strain and a C. botulinum Group I type A strain. Specifically, the measured heat resistance 
of C. botulinum Group II type E strain increased by 1800-fold when lysozyme was present in 
the recovery medium, whereas the heat resistance of C. botulinum Group I type A strain 
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only increased up to 3-fold with the addition of lysozyme (Alderton et al., 1974). The results 
for the Group II strain is similar to that reported in the current study and by others (e.g. 
Peck et al. (1993)). The small (3-fold) increase in recovery for the Group I strain reported by 
Alderton et al. (1974) may reflect strain dependency or a loss of spores in the current work 
during the washing procedure. The decoating solution was changed during the current 
study from dithiothreitol to sodium thioglycolate, but this change had no effect on the 
number of colonies formed from heat inactivated spores on medium supplemented with 
lysozyme (data not shown).  
To determine which part of the germination apparatus in Group I strain Af84 and Group II 
strain Eklund 17B is damaged by heating, a nutrient and non-nutrient germinant were 
included in the recovery protocol for heat-inactivated spores. In the current study,  
recovery of heat damaged spores of Group I strain Af84 and Group II strain Eklund 17B with 
DDA or L-alanine in the recovery medium was unsuccessful. During a study by Trunet et al. 
(2015), attempts to recover heat killed spores of B. weihenstephanensis and B. licheniformis 
with medium supplemented with an alanine-inosine mix and lysozyme were unsuccessful, 
even though spores of B. weihenstephanensis and B. licheniformis have previously been 
shown to germinate in response to these stimuli (Garcia et al., 2010, Madslien et al., 2014). 
Similarly, a study by Coleman and Setlow (2009) found that the addition of L-alanine and 
other amino acids, such as L-arginine and L-glutamine, did not affect recovery of heat 
inactivated spores if glucose was omitted from the recovery medium. In the present study, 
CaDPA did not induce germination in spores of Group I strain Af84 or Group II strain Eklund 
17B and therefore, heat inactivation and recovery of spores with CaDPA in the recovery 
medium was not tested. A previous publication by Cazemier et al. (2001) reported that the 
recovery of heat-injured spores increased by 0.5-log with medium supplemented with 
CaDPA in strains of B. subtilis, which prompted the hypothesis that the germinant receptor 
proteins were damaged by heat. At present, studies evaluating the capability of DDA to 
recover heat-inactivated spores are limited and therefore, no comparisons can be made 
between previously published data and the results obtained in the current study.  
The inability to recover heat-inactivated spores of Group I strain Af84 with nutrient 
germinants, DDA or lysozyme leaves it unresolved as to whether part of the spore 
germination apparatus is damaged by heating, or whether another part of the spore is 
damaged. The ability of lysozyme, but not DDA or nutrient germinants, to recover heat-
inactivated spores of Group II strain Eklund 17B indicates that part of the germination 
apparatus is damaged by heating, possibly the germinant receptors, SpoVA proteins, cortex 
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lytic enzymes, or another presently unknown structure. The germination pathways in C. 
botulinum Group I and II were proposed by Brunt et al. (2016), however, it was unknown as 
to whether DPA precedes cortex hydrolysis or vice versa. Some advancement has been 
made during the current study to try and determine this unknown and it is evident that 
DPA release, especially in Group II strain Eklund 17B, occurs early on during germination. 
However, it is still unclear whether cortex hydrolysis occurs as a result of DPA release in C. 
botulinum Group I and Group II, as attempts to determine the presence of certain cortex 
fragments in the supernatant of germinating spores of Group I and Group II was 
unsuccessful (data not shown). A previous study by Francis et al. (2015), demonstrated that 
cortex hydrolysis is initiated before DPA release in spores of C. difficile, which is in contrast 
to previous findings in which DPA release causes cortex hydrolysis in B. subtilis and C. 
perfringens (Paredes-Sabja et al., 2009a, Setlow et al., 2008). 
 
4.7 DPA content of spores 
The DPA concentration of spores of Group I strain Af84 and Group II strain Eklund 17B was 
estimated during the current study. The DPA concentration for spores of Group II strain 
Eklund 17B was calculated to be 2.1pg/spore of DPA, compared to 1.9pg/spore of DPA per 
spore of Group I strain Af84. The DPA concentration per spore in Clostridium varies 
between species and strain, for example, spores of C. beijerinckii strain DSM 791 contained 
0.09pg DPA per spore, whereas spores of another strain of C. beijerinckii contained 4.4pg 
DPA per spore (Jamroskovic et al., 2016). In the same study, it was found that DPA content 
in spores of C. acetobutylicum ranged from 1.98pg to 2.6pg DPA per spore. DPA in the 
spore core contributes to overall spore heat resistance, but there are a variety of other 
factors that are also involved, such as low water content, presence of small acid-soluble 
proteins (SASPs), and spore structures, including the coat and inner membrane (Paidhungat 
et al., 2000, Setlow et al., 2006). In the current study, the two strains of C. botulinum used 
had a similar DPA content per spore, even though Group II strain Eklund 17B is less heat 
resistant than Group I strain Af84, suggesting that other factors are involved in providing 
the spore with heat resistance properties and not solely DPA content. Similarly, there has 
been no correlation identified between spore heat resistance and DPA content in previous 
publications investigating heat resistance of spores, suggesting that a large amount of DPA 
in the spore core does not necessarily mean that the spore will have a high heat resistance, 
which also indicates that other elements, in combination, protect the spore from heat 
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damage (Grecz and Tang, 1970, Kort et al., 2005). The lack of relationship between DPA 
content and heat resistance may explain why Group II strain Eklund 17B in the current 
study has a similar amount of DPA per spore, however is less heat resistant, than Group I 
strain Af84. In the study by Grecz and Tang (1970), the least heat resistant strain (C. 
botulinum Type E strain VHE) had approximately the same amount of DPA as the most heat 
resistant strain (C. botulinum Type B strain 41B), however there was a correlation between 
heat resistance and the rate DPA was expelled from the spore core. Less than 1% (0.26% 
and 0.14% for Group I and II, respectively) of the spore DPA was released in the 
germination tests carried out.  
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5. Conclusion and Future Research 
Results from this study have allowed revisions to be made to the proposed germination 
pathways in C. botulinum Group I and Group II, as described by Brunt et al. (2016) (Figure 
27). Important differences in the two germination pathways have been identified, including 
a reliance on alternative germinant receptors and spore lytic enzymes. Additionally spores 
of Group I are more heat resistant that those of Group II. In the current study, spores of 
Group I strain Af84 and Group II strain Eklund 17B were heated at 95°C for 4 hours and 
85°C for 2 minutes, respectively. Spores of Group I strain Af84 were not recovered with any 
of the germinants used during this study, and it is unclear whether the heat treatment 
damages the germination apparatus or another part of spore, and whether this damage is 
reversible. The ability of Group II strain Eklund 17B to be recovered with lysozyme, but not 
nutrient germinants or DDA, indicates that part of the germination apparatus, possibly the 
cortex lytic enzymes, germinant receptors, SpoVA proteins or an unknown structure is 
damaged by heat. The inclusion of lysozyme in the recovery medium overcomes this heat 
damage.  
Germination in Group I and Group II strains with nutrient and non-nutrient germinants is 
strain and species specific and hence, more research needs to be done on C. botulinum 
using a larger number of strains of each Group in order to define the germination pathway 
fully. Furthermore, deciphering the timing of DPA release and cortex hydrolysis in spores of 
C. botulinum Group I and Group II using a cortex fragment assay that detects the presence 
of NAG residues, will advance knowledge on germination in C. botulinum and potentially 
result in prevention of germination of spores, leading to a reduction in cell outgrowth and 
toxin formation. Future research will involve using the Clostron method to make mutants 
of spores of Group I strain Af84 and Group II strain Eklund 17B and the use of non-nutrient 
germinants that have been identified that bypass the germinant receptors, in order to 
confirm the part of the germination apparatus that is damaged by heat.  
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Figure 27. Revised germination pathway diagram in C. botulinum Group I strain Af84 and Group 
II strain Eklund 17B, showing whether the nutrient and non-nutrient inputs successfully 
germinated strains of C. botulinum. (1) Germination of both strains occurred with L-alanine and 
L-cysteine, however no recovery of heat-inactivated spores occurred with L-alanine, suggesting 
that the germinant receptors may be damaged by heat. (2) Dodecylamine (DDA) induces 
germination in both strains, possibly through SpoVA channels, however other unknown coat 
proteins may be required during germination because removing the coat of spores prevented 
germination. DDA did not recover heated spores, therefore this part of the apparatus may be 
damaged by heat. (3) Exogenous CaDPA did not germinate strains of C. botulinum used during 
this study, so no conclusion can be made as to whether heat damages cortex lytic enzymes in 
Group I and II or germinant receptors homologous to Gerk in Group II. (4) Lysozyme germinates 
spores of both strains if the spore coat is removed. Heated spores of Group II strain Eklund 17B 
are recovered with lysozyme, suggesting that the DNA is not damaged but maybe an earlier part 
of the spore germination apparatus is damaged by heat (*Group I strain Af84 cannot be 
recovered with lysozyme and is prone to osmotic rupture). (5) DPA appears to be released 
before or at a similar time, to cortex hydrolysis.  
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